<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Perjeta-II-48 EN PI clean</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:BISansCond;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;}
@font-face
	{font-family:"Bahnschrift Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Bahnschrift;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight SemiConde";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold SemiConden";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Candara;
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Candara Light";
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:Constantia;
	panose-1:2 3 6 2 5 3 6 3 3 3;}
@font-face
	{font-family:Corbel;
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"Corbel Light";
	panose-1:2 11 3 3 2 2 4 2 2 4;}
@font-face
	{font-family:Ebrima;
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;}
@font-face
	{font-family:Gabriola;
	panose-1:4 4 6 5 5 16 2 2 13 2;}
@font-face
	{font-family:Gadugi;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;}
@font-face
	{font-family:"Ink Free";
	panose-1:3 8 4 2 0 5 0 0 0 0;}
@font-face
	{font-family:"Javanese Text";
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Leelawadee UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Leelawadee UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;}
@font-face
	{font-family:"\@Malgun Gothic";}
@font-face
	{font-family:"Malgun Gothic Semilight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Malgun Gothic Semilight";}
@font-face
	{font-family:"Microsoft Himalaya";
	panose-1:1 1 1 0 1 1 1 1 1 1;}
@font-face
	{font-family:"Microsoft JhengHei";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei";}
@font-face
	{font-family:"Microsoft JhengHei UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI";}
@font-face
	{font-family:"Microsoft JhengHei Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei Light";}
@font-face
	{font-family:"Microsoft JhengHei UI Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI Light";}
@font-face
	{font-family:"Microsoft New Tai Lue";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft PhagsPa";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Microsoft Tai Le";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft YaHei";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei";}
@font-face
	{font-family:"Microsoft YaHei UI";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei UI";}
@font-face
	{font-family:"Microsoft YaHei Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei Light";}
@font-face
	{font-family:"Microsoft YaHei UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei UI Light";}
@font-face
	{font-family:"Microsoft Yi Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:MingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU-ExtB";}
@font-face
	{font-family:PMingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@PMingLiU-ExtB";}
@font-face
	{font-family:MingLiU_HKSCS-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU_HKSCS-ExtB";}
@font-face
	{font-family:"Mongolian Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"MS UI Gothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS UI Gothic";}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS PGothic";}
@font-face
	{font-family:"MV Boli";
	panose-1:2 0 5 0 3 2 0 9 0 0;}
@font-face
	{font-family:"Myanmar Text";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Segoe Print";
	panose-1:2 0 6 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe Script";
	panose-1:3 11 5 4 2 0 0 0 0 3;}
@font-face
	{font-family:"Segoe UI Black";
	panose-1:2 11 10 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Historic";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:NSimSun;
	panose-1:2 1 6 9 3 1 1 1 1 1;}
@font-face
	{font-family:"\@NSimSun";}
@font-face
	{font-family:SimSun-ExtB;
	panose-1:2 1 6 9 6 1 1 1 1 1;}
@font-face
	{font-family:"\@SimSun-ExtB";}
@font-face
	{font-family:"Sitka Small";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Text";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Subheading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Heading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Display";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Banner";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;}
@font-face
	{font-family:"\@Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Yu Gothic UI";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI";}
@font-face
	{font-family:"Yu Gothic UI Semibold";
	panose-1:2 11 7 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semibold";}
@font-face
	{font-family:"Yu Gothic Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Light";}
@font-face
	{font-family:"Yu Gothic UI Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Light";}
@font-face
	{font-family:"Yu Gothic Medium";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Medium";}
@font-face
	{font-family:"Yu Gothic UI Semilight";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semilight";}
@font-face
	{font-family:"HoloLens MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Agency FB";
	panose-1:2 11 5 3 2 2 2 2 2 4;}
@font-face
	{font-family:Algerian;
	panose-1:4 2 7 5 4 10 2 6 7 2;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;}
@font-face
	{font-family:"Arial Rounded MT Bold";
	panose-1:2 15 7 4 3 5 4 3 2 4;}
@font-face
	{font-family:"Baskerville Old Face";
	panose-1:2 2 6 2 8 5 5 2 3 3;}
@font-face
	{font-family:"Bauhaus 93";
	panose-1:4 3 9 5 2 11 2 2 12 2;}
@font-face
	{font-family:"Bell MT";
	panose-1:2 2 5 3 6 3 5 2 3 3;}
@font-face
	{font-family:"Bernard MT Condensed";
	panose-1:2 5 8 6 6 9 5 2 4 4;}
@font-face
	{font-family:"Bodoni MT";
	panose-1:2 7 6 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Black";
	panose-1:2 7 10 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Condensed";
	panose-1:2 7 6 6 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Poster Compressed";
	panose-1:2 7 7 6 8 6 1 5 2 4;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;}
@font-face
	{font-family:"Bradley Hand ITC";
	panose-1:3 7 4 2 5 3 2 3 2 3;}
@font-face
	{font-family:"Britannic Bold";
	panose-1:2 11 9 3 6 7 3 2 2 4;}
@font-face
	{font-family:"Berlin Sans FB";
	panose-1:2 14 6 2 2 5 2 2 3 6;}
@font-face
	{font-family:"Berlin Sans FB Demi";
	panose-1:2 14 8 2 2 5 2 2 3 6;}
@font-face
	{font-family:Broadway;
	panose-1:4 4 9 5 8 11 2 2 5 2;}
@font-face
	{font-family:"Brush Script MT";
	panose-1:3 6 8 2 4 4 6 7 3 4;}
@font-face
	{font-family:"Bookshelf Symbol 7";
	panose-1:5 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Californian FB";
	panose-1:2 7 4 3 6 8 11 3 2 4;}
@font-face
	{font-family:"Calisto MT";
	panose-1:2 4 6 3 5 5 5 3 3 4;}
@font-face
	{font-family:Castellar;
	panose-1:2 10 4 2 6 4 6 1 3 1;}
@font-face
	{font-family:"Century Schoolbook";
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:Centaur;
	panose-1:2 3 5 4 5 2 5 2 3 4;}
@font-face
	{font-family:Chiller;
	panose-1:4 2 4 4 3 16 7 2 6 2;}
@font-face
	{font-family:"Colonna MT";
	panose-1:4 2 8 5 6 2 2 3 2 3;}
@font-face
	{font-family:"Cooper Black";
	panose-1:2 8 9 4 4 3 11 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Bold";
	panose-1:2 14 7 5 2 2 6 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Light";
	panose-1:2 14 5 7 2 2 6 2 4 4;}
@font-face
	{font-family:"Curlz MT";
	panose-1:4 4 4 4 5 7 2 2 2 2;}
@font-face
	{font-family:Dubai;
	panose-1:2 11 5 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Light";
	panose-1:2 11 3 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Medium";
	panose-1:2 11 6 3 3 4 3 3 2 4;}
@font-face
	{font-family:Elephant;
	panose-1:2 2 9 4 9 5 5 2 3 3;}
@font-face
	{font-family:"Engravers MT";
	panose-1:2 9 7 7 8 5 5 2 3 4;}
@font-face
	{font-family:"Eras Bold ITC";
	panose-1:2 11 9 7 3 5 4 2 2 4;}
@font-face
	{font-family:"Eras Demi ITC";
	panose-1:2 11 8 5 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Light ITC";
	panose-1:2 11 4 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Medium ITC";
	panose-1:2 11 6 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Felix Titling";
	panose-1:4 6 5 5 6 2 2 2 10 4;}
@font-face
	{font-family:Forte;
	panose-1:3 6 9 2 4 5 2 7 2 3;}
@font-face
	{font-family:"Franklin Gothic Book";
	panose-1:2 11 5 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi";
	panose-1:2 11 7 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi Cond";
	panose-1:2 11 7 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Heavy";
	panose-1:2 11 9 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Medium Cond";
	panose-1:2 11 6 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Freestyle Script";
	panose-1:3 8 4 2 3 2 5 11 4 4;}
@font-face
	{font-family:"French Script MT";
	panose-1:3 2 4 2 4 6 7 4 6 5;}
@font-face
	{font-family:"Footlight MT Light";
	panose-1:2 4 6 2 6 3 10 2 3 4;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;}
@font-face
	{font-family:Gigi;
	panose-1:4 4 5 4 6 16 7 2 13 2;}
@font-face
	{font-family:"Gill Sans MT";
	panose-1:2 11 5 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans MT Condensed";
	panose-1:2 11 5 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold Condensed";
	panose-1:2 11 10 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold";
	panose-1:2 11 10 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gloucester MT Extra Condensed";
	panose-1:2 3 8 8 2 6 1 1 1 1;}
@font-face
	{font-family:"Gill Sans MT Ext Condensed Bold";
	panose-1:2 11 9 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;}
@font-face
	{font-family:"Goudy Old Style";
	panose-1:2 2 5 2 5 3 5 2 3 3;}
@font-face
	{font-family:"Goudy Stout";
	panose-1:2 2 9 4 7 3 11 2 4 1;}
@font-face
	{font-family:"Harlow Solid Italic";
	panose-1:4 3 6 4 2 15 2 2 13 2;}
@font-face
	{font-family:Harrington;
	panose-1:4 4 5 5 5 10 2 2 7 2;}
@font-face
	{font-family:Haettenschweiler;
	panose-1:2 11 7 6 4 9 2 6 2 4;}
@font-face
	{font-family:"High Tower Text";
	panose-1:2 4 5 2 5 5 6 3 3 3;}
@font-face
	{font-family:"Imprint MT Shadow";
	panose-1:4 2 6 5 6 3 3 3 2 2;}
@font-face
	{font-family:"Informal Roman";
	panose-1:3 6 4 2 3 4 6 11 2 4;}
@font-face
	{font-family:"Blackadder ITC";
	panose-1:4 2 5 5 5 16 7 2 13 2;}
@font-face
	{font-family:"Edwardian Script ITC";
	panose-1:3 3 3 2 4 7 7 13 8 4;}
@font-face
	{font-family:"Kristen ITC";
	panose-1:3 5 5 2 4 2 2 3 2 2;}
@font-face
	{font-family:Jokerman;
	panose-1:4 9 6 5 6 13 6 2 7 2;}
@font-face
	{font-family:"Juice ITC";
	panose-1:4 4 4 3 4 10 2 2 2 2;}
@font-face
	{font-family:"Kunstler Script";
	panose-1:3 3 4 2 2 6 7 13 13 6;}
@font-face
	{font-family:"Wide Latin";
	panose-1:2 10 10 7 5 5 5 2 4 4;}
@font-face
	{font-family:"Lucida Bright";
	panose-1:2 4 6 2 5 5 5 2 3 4;}
@font-face
	{font-family:"Lucida Calligraphy";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Fax";
	panose-1:2 6 6 2 5 5 5 2 2 4;}
@font-face
	{font-family:"Lucida Handwriting";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Sans";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Typewriter";
	panose-1:2 11 5 9 3 5 4 3 2 4;}
@font-face
	{font-family:Magneto;
	panose-1:4 3 8 5 5 8 2 2 13 2;}
@font-face
	{font-family:"Maiandra GD";
	panose-1:2 14 5 2 3 3 8 2 2 4;}
@font-face
	{font-family:"Matura MT Script Capitals";
	panose-1:3 2 8 2 6 6 2 7 2 2;}
@font-face
	{font-family:Mistral;
	panose-1:3 9 7 2 3 4 7 2 4 3;}
@font-face
	{font-family:"Modern No\. 20";
	panose-1:2 7 7 4 7 5 5 2 3 3;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;}
@font-face
	{font-family:"Niagara Engraved";
	panose-1:4 2 5 2 7 7 3 3 2 2;}
@font-face
	{font-family:"Niagara Solid";
	panose-1:4 2 5 2 7 7 2 2 2 2;}
@font-face
	{font-family:"OCR A Extended";
	panose-1:2 1 5 9 2 1 2 1 3 3;}
@font-face
	{font-family:"Old English Text MT";
	panose-1:3 4 9 2 4 5 8 3 8 6;}
@font-face
	{font-family:Onyx;
	panose-1:4 5 6 2 8 7 2 2 2 3;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 1 1 0 1 0 0 0 0 0;}
@font-face
	{font-family:"Palace Script MT";
	panose-1:3 3 3 2 2 6 7 12 11 5;}
@font-face
	{font-family:Papyrus;
	panose-1:3 7 5 2 6 5 2 3 2 5;}
@font-face
	{font-family:Parchment;
	panose-1:3 4 6 2 4 7 8 4 8 4;}
@font-face
	{font-family:Perpetua;
	panose-1:2 2 5 2 6 4 1 2 3 3;}
@font-face
	{font-family:"Perpetua Titling MT";
	panose-1:2 2 5 2 6 5 5 2 8 4;}
@font-face
	{font-family:Playbill;
	panose-1:4 5 6 3 10 6 2 2 2 2;}
@font-face
	{font-family:"Poor Richard";
	panose-1:2 8 5 2 5 5 5 2 7 2;}
@font-face
	{font-family:Pristina;
	panose-1:3 6 4 2 4 4 6 8 2 4;}
@font-face
	{font-family:"Rage Italic";
	panose-1:3 7 5 2 4 5 7 7 3 4;}
@font-face
	{font-family:Ravie;
	panose-1:4 4 8 5 5 8 9 2 6 2;}
@font-face
	{font-family:"MS Reference Sans Serif";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"MS Reference Specialty";
	panose-1:5 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Rockwell Condensed";
	panose-1:2 6 6 3 5 4 5 2 1 4;}
@font-face
	{font-family:Rockwell;
	panose-1:2 6 6 3 2 2 5 2 4 3;}
@font-face
	{font-family:"Rockwell Extra Bold";
	panose-1:2 6 9 3 4 5 5 2 4 3;}
@font-face
	{font-family:"Script MT Bold";
	panose-1:3 4 6 2 4 6 7 8 9 4;}
@font-face
	{font-family:"Showcard Gothic";
	panose-1:4 2 9 4 2 1 2 2 6 4;}
@font-face
	{font-family:"Snap ITC";
	panose-1:4 4 10 7 6 10 2 2 2 2;}
@font-face
	{font-family:Stencil;
	panose-1:4 4 9 5 13 8 2 2 4 4;}
@font-face
	{font-family:"Tw Cen MT";
	panose-1:2 11 6 2 2 1 4 2 6 3;}
@font-face
	{font-family:"Tw Cen MT Condensed";
	panose-1:2 11 6 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Tw Cen MT Condensed Extra Bold";
	panose-1:2 11 8 3 2 2 2 2 2 4;}
@font-face
	{font-family:"Tempus Sans ITC";
	panose-1:4 2 4 4 3 13 7 2 2 2;}
@font-face
	{font-family:"Viner Hand ITC";
	panose-1:3 7 5 2 3 5 2 2 2 3;}
@font-face
	{font-family:Vivaldi;
	panose-1:3 2 6 2 5 5 6 9 8 4;}
@font-face
	{font-family:"Vladimir Script";
	panose-1:3 5 4 2 4 4 7 7 3 5;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;}
@font-face
	{font-family:AngsanaUPC;}
@font-face
	{font-family:CordiaUPC;}
@font-face
	{font-family:Abadi;}
@font-face
	{font-family:"Abadi Extra Light";}
@font-face
	{font-family:Aharoni;}
@font-face
	{font-family:Aldhabi;}
@font-face
	{font-family:Aparajita;}
@font-face
	{font-family:"Arabic Typesetting";}
@font-face
	{font-family:"Arial Nova";}
@font-face
	{font-family:"Arial Nova Cond";}
@font-face
	{font-family:"Arial Nova Cond Light";}
@font-face
	{font-family:"Arial Nova Light";}
@font-face
	{font-family:"Avenir Next LT Pro";}
@font-face
	{font-family:"Avenir Next LT Pro Light";}
@font-face
	{font-family:BatangChe;}
@font-face
	{font-family:Bembo;}
@font-face
	{font-family:Biome;}
@font-face
	{font-family:"Biome Light";}
@font-face
	{font-family:"Browallia New";}
@font-face
	{font-family:BrowalliaUPC;}
@font-face
	{font-family:Cavolini;}
@font-face
	{font-family:Dante;}
@font-face
	{font-family:DaunPenh;}
@font-face
	{font-family:David;}
@font-face
	{font-family:Daytona;}
@font-face
	{font-family:"Daytona Condensed";}
@font-face
	{font-family:"Daytona Condensed Light";}
@font-face
	{font-family:"Daytona Light";}
@font-face
	{font-family:"DengXian Light";}
@font-face
	{font-family:DilleniaUPC;}
@font-face
	{font-family:DokChampa;}
@font-face
	{font-family:DotumChe;}
@font-face
	{font-family:"Elephant Pro";}
@font-face
	{font-family:EucrosiaUPC;}
@font-face
	{font-family:Euphemia;}
@font-face
	{font-family:FangSong;}
@font-face
	{font-family:FrankRuehl;}
@font-face
	{font-family:FreesiaUPC;}
@font-face
	{font-family:"Georgia Pro";}
@font-face
	{font-family:"Georgia Pro Black";}
@font-face
	{font-family:"Georgia Pro Cond";}
@font-face
	{font-family:"Georgia Pro Cond Black";}
@font-face
	{font-family:"Georgia Pro Cond Light";}
@font-face
	{font-family:"Georgia Pro Cond Semibold";}
@font-face
	{font-family:"Georgia Pro Light";}
@font-face
	{font-family:"Georgia Pro Semibold";}
@font-face
	{font-family:"Gill Sans Nova";}
@font-face
	{font-family:"Gill Sans Nova Cond";}
@font-face
	{font-family:"Gill Sans Nova Cond Lt";}
@font-face
	{font-family:"Gill Sans Nova Cond Ultra Bold";}
@font-face
	{font-family:"Gill Sans Nova Cond XBd";}
@font-face
	{font-family:"Gill Sans Nova Light";}
@font-face
	{font-family:"Gill Sans Nova Ultra Bold";}
@font-face
	{font-family:Gisha;}
@font-face
	{font-family:Grotesque;}
@font-face
	{font-family:"Grotesque Light";}
@font-face
	{font-family:GulimChe;}
@font-face
	{font-family:Gungsuh;}
@font-face
	{font-family:GungsuhChe;}
@font-face
	{font-family:"Hadassah Friedlaender";}
@font-face
	{font-family:HGGothicE;}
@font-face
	{font-family:HGMaruGothicMPRO;}
@font-face
	{font-family:HGMinchoE;}
@font-face
	{font-family:HGPGothicE;}
@font-face
	{font-family:HGPMinchoE;}
@font-face
	{font-family:HGPSoeiKakugothicUB;}
@font-face
	{font-family:HGSGothicE;}
@font-face
	{font-family:HGSMinchoE;}
@font-face
	{font-family:HGSoeiKakugothicUB;}
@font-face
	{font-family:HGSSoeiKakugothicUB;}
@font-face
	{font-family:IrisUPC;}
@font-face
	{font-family:"Iskoola Pota";}
@font-face
	{font-family:JasmineUPC;}
@font-face
	{font-family:KaiTi;}
@font-face
	{font-family:Kalinga;}
@font-face
	{font-family:Kartika;}
@font-face
	{font-family:"Khmer UI";}
@font-face
	{font-family:Kigelia;}
@font-face
	{font-family:"Kigelia Arabic";}
@font-face
	{font-family:"Kigelia Arabic Light";}
@font-face
	{font-family:"Kigelia Light";}
@font-face
	{font-family:KodchiangUPC;}
@font-face
	{font-family:Kokila;}
@font-face
	{font-family:"Lao UI";}
@font-face
	{font-family:Leelawadee;}
@font-face
	{font-family:"Levenim MT";}
@font-face
	{font-family:LilyUPC;}
@font-face
	{font-family:"Mangal Pro";}
@font-face
	{font-family:Meiryo;}
@font-face
	{font-family:"Meiryo UI";}
@font-face
	{font-family:"Microsoft GothicNeo";}
@font-face
	{font-family:"Microsoft GothicNeo Light";}
@font-face
	{font-family:"Microsoft Uighur";}
@font-face
	{font-family:MingLiU_HKSCS;}
@font-face
	{font-family:Miriam;}
@font-face
	{font-family:"Miriam Fixed";}
@font-face
	{font-family:"Modern Love";}
@font-face
	{font-family:"Modern Love Caps";}
@font-face
	{font-family:"Modern Love Grunge";}
@font-face
	{font-family:MoolBoran;}
@font-face
	{font-family:"MS PMincho";}
@font-face
	{font-family:"MT Extra";}
@font-face
	{font-family:Narkisim;}
@font-face
	{font-family:"Neue Haas Grotesk Text Pro";}
@font-face
	{font-family:"News Gothic MT";}
@font-face
	{font-family:Nyala;}
@font-face
	{font-family:OCRB;}
@font-face
	{font-family:"Plantagenet Cherokee";}
@font-face
	{font-family:Posterama;}
@font-face
	{font-family:"Quire Sans";}
@font-face
	{font-family:"Quire Sans Light";}
@font-face
	{font-family:"Quire Sans Pro Light";}
@font-face
	{font-family:"Rockwell Light";}
@font-face
	{font-family:"Rockwell Nova";}
@font-face
	{font-family:"Rockwell Nova Cond";}
@font-face
	{font-family:"Rockwell Nova Cond Light";}
@font-face
	{font-family:"Rockwell Nova Extra Bold";}
@font-face
	{font-family:"Rockwell Nova Light";}
@font-face
	{font-family:Rod;}
@font-face
	{font-family:"Sabon Next LT";}
@font-face
	{font-family:"Sagona Book";}
@font-face
	{font-family:"Sagona ExtraLight";}
@font-face
	{font-family:"Sakkal Majalla";}
@font-face
	{font-family:"Sanskrit Text";}
@font-face
	{font-family:Selawik;}
@font-face
	{font-family:"Selawik Light";}
@font-face
	{font-family:"Selawik Semibold";}
@font-face
	{font-family:"Shonar Bangla";}
@font-face
	{font-family:"Simplified Arabic";}
@font-face
	{font-family:"Simplified Arabic Fixed";}
@font-face
	{font-family:"Sitka Banner Semibold";}
@font-face
	{font-family:"Sitka Display Semibold";}
@font-face
	{font-family:"Sitka Heading Semibold";}
@font-face
	{font-family:"Sitka Small Semibold";}
@font-face
	{font-family:"Sitka Subheading Semibold";}
@font-face
	{font-family:"Sitka Text Semibold";}
@font-face
	{font-family:"Source Sans Pro";}
@font-face
	{font-family:"Source Sans Pro Black";}
@font-face
	{font-family:"Source Sans Pro ExtraLight";}
@font-face
	{font-family:"Source Sans Pro Light";}
@font-face
	{font-family:"Source Sans Pro SemiBold";}
@font-face
	{font-family:"Speak Pro";}
@font-face
	{font-family:"Speak Pro Light";}
@font-face
	{font-family:STCaiyun;}
@font-face
	{font-family:STFangsong;}
@font-face
	{font-family:STHupo;}
@font-face
	{font-family:STKaiti;}
@font-face
	{font-family:STXihei;}
@font-face
	{font-family:STXingkai;}
@font-face
	{font-family:STXinwei;}
@font-face
	{font-family:STZhongsong;}
@font-face
	{font-family:"TH SarabunPSK";}
@font-face
	{font-family:"The Hand";}
@font-face
	{font-family:"The Hand Black";}
@font-face
	{font-family:"The Hand Extrablack";}
@font-face
	{font-family:"The Hand Light";}
@font-face
	{font-family:"The Serif Hand";}
@font-face
	{font-family:"The Serif Hand Black";}
@font-face
	{font-family:"The Serif Hand Extrablack";}
@font-face
	{font-family:"The Serif Hand Light";}
@font-face
	{font-family:"Tisa Offc Serif Pro";}
@font-face
	{font-family:"Tisa Offc Serif Pro Thin";}
@font-face
	{font-family:"Trade Gothic Next";}
@font-face
	{font-family:"Trade Gothic Next Cond";}
@font-face
	{font-family:"Trade Gothic Next Cond Hv";}
@font-face
	{font-family:"Trade Gothic Next Heavy";}
@font-face
	{font-family:"Trade Gothic Next Light";}
@font-face
	{font-family:"Traditional Arabic";}
@font-face
	{font-family:"UD Digi Kyokasho N-B";}
@font-face
	{font-family:"UD Digi Kyokasho N-R";}
@font-face
	{font-family:"UD Digi Kyokasho NK-B";}
@font-face
	{font-family:"UD Digi Kyokasho NK-R";}
@font-face
	{font-family:"UD Digi Kyokasho NP-B";}
@font-face
	{font-family:"UD Digi Kyokasho NP-R";}
@font-face
	{font-family:Univers;}
@font-face
	{font-family:"Univers Condensed";}
@font-face
	{font-family:"Univers Condensed Light";}
@font-face
	{font-family:"Univers Light";}
@font-face
	{font-family:"Urdu Typesetting";}
@font-face
	{font-family:Utsaah;}
@font-face
	{font-family:Vani;}
@font-face
	{font-family:"Verdana Pro";}
@font-face
	{font-family:"Verdana Pro Black";}
@font-face
	{font-family:"Verdana Pro Cond";}
@font-face
	{font-family:"Verdana Pro Cond Black";}
@font-face
	{font-family:"Verdana Pro Cond Light";}
@font-face
	{font-family:"Verdana Pro Cond SemiBold";}
@font-face
	{font-family:"Verdana Pro Light";}
@font-face
	{font-family:"Verdana Pro SemiBold";}
@font-face
	{font-family:Vijaya;}
@font-face
	{font-family:"Walbaum Display";}
@font-face
	{font-family:"Walbaum Display Heavy";}
@font-face
	{font-family:"Walbaum Display Light";}
@font-face
	{font-family:"Walbaum Display SemiBold";}
@font-face
	{font-family:"Walbaum Heading";}
@font-face
	{font-family:"Walbaum Text";}
@font-face
	{font-family:"Yu Mincho";}
@font-face
	{font-family:"Yu Mincho Demibold";}
@font-face
	{font-family:"Yu Mincho Light";}
@font-face
	{font-family:"TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPSMT;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:2 2 8 3 7 5 5 2 3 4;}
@font-face
	{font-family:PraxisCom-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EUAlbertina;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"\@TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@Batang";
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@BatangChe";}
@font-face
	{font-family:"\@Gungsuh";}
@font-face
	{font-family:"\@GungsuhChe";}
@font-face
	{font-family:"\@DengXian Light";}
@font-face
	{font-family:"\@Gulim";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@GulimChe";}
@font-face
	{font-family:"\@Dotum";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@DotumChe";}
@font-face
	{font-family:"\@Meiryo";}
@font-face
	{font-family:"\@Meiryo UI";}
@font-face
	{font-family:"\@MingLiU";
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:"\@PMingLiU";
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"\@MingLiU_HKSCS";}
@font-face
	{font-family:"\@MS PMincho";}
@font-face
	{font-family:"\@STXingkai";}
@font-face
	{font-family:"\@STZhongsong";}
@font-face
	{font-family:"\@Yu Mincho";}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Times-Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:CourierNewPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"SAS Monospace";}
@font-face
	{font-family:"Bookshelf Symbol 3";}
@font-face
	{font-family:Goudy;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Garamond-Italic;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:DIN-Bold;}
@font-face
	{font-family:"CG Times \(W1\)";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"HelveticaNeue Condensed";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@HGMaruGothicMPRO";}
@font-face
	{font-family:CourierStd;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EFPPNA+TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@TimesNewRoman";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRomanPSMT\,Times New Rom";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,Times New Roman";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"CG Times";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Minion;}
@font-face
	{font-family:CourierNew;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Noto Sans Symbols";}
@font-face
	{font-family:LZLLQG+TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPS;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:HelveticaNeueLTStd-Cn;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@HelveticaNeueLTStd-Cn";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Wingdings-Regular";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Geneva;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,BoldItalic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:ArialMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{mso-style-link:"Heading 1 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
h2
	{mso-style-link:"Heading 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h3
	{mso-style-link:"Heading 3 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:13.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
h4
	{mso-style-link:"Heading 4 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:1.0pt;
	margin-left:70.55pt;
	text-indent:-70.55pt;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:13.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
h5
	{mso-style-link:"Heading 5 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:1.0pt;
	margin-left:.3in;
	text-indent:-.3in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:13.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
h6
	{mso-style-link:"Heading 6 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:1.0pt;
	margin-left:.3in;
	text-indent:-.3in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:13.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-link:"Heading 7 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:1.0pt;
	margin-left:.3in;
	text-indent:-.3in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:13.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-link:"Heading 8 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:1.0pt;
	margin-left:.3in;
	text-indent:-.3in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:13.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{mso-style-link:"Heading 9 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:1.0pt;
	margin-left:.3in;
	text-indent:-.3in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:13.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoIndex1, li.MsoIndex1, div.MsoIndex1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex2, li.MsoIndex2, div.MsoIndex2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex3, li.MsoIndex3, div.MsoIndex3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex4, li.MsoIndex4, div.MsoIndex4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex5, li.MsoIndex5, div.MsoIndex5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex6, li.MsoIndex6, div.MsoIndex6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex7, li.MsoIndex7, div.MsoIndex7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex8, li.MsoIndex8, div.MsoIndex8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex9, li.MsoIndex9, div.MsoIndex9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:99.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin-top:11.35pt;
	margin-right:1.0in;
	margin-bottom:5.65pt;
	margin-left:.35in;
	text-indent:-.35in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:1.0in;
	margin-bottom:5.65pt;
	margin-left:1.35in;
	text-indent:-1.0in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:1.0in;
	margin-bottom:5.65pt;
	margin-left:.5in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:0in;
	margin-right:1.0in;
	margin-bottom:5.65pt;
	margin-left:.75in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:0in;
	margin-right:1.0in;
	margin-bottom:5.65pt;
	margin-left:1.0in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:96.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNormalIndent, li.MsoNormalIndent, div.MsoNormalIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-link:"Comment Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin:0in;
	font-size:8.0pt;
	font-family:"Arial",sans-serif;}
p.MsoIndexHeading, li.MsoIndexHeading, div.MsoIndexHeading
	{margin:0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoTof, li.MsoTof, div.MsoTof
	{margin-top:0in;
	margin-right:28.1pt;
	margin-bottom:0in;
	margin-left:1.1in;
	text-indent:-1.1in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoEnvelopeAddress, li.MsoEnvelopeAddress, div.MsoEnvelopeAddress
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.0in;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.MsoEnvelopeReturn, li.MsoEnvelopeReturn, div.MsoEnvelopeReturn
	{margin:0in;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
span.MsoCommentReference
	{font-family:"Times New Roman",serif;}
span.MsoPageNumber
	{font-family:"Arial",sans-serif;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToa, li.MsoToa, div.MsoToa
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMacroText, li.MsoMacroText, div.MsoMacroText
	{margin:0in;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoToaHeading, li.MsoToaHeading, div.MsoToaHeading
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoList, li.MsoList, div.MsoList
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:.3in;
	text-indent:-.3in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber, li.MsoListNumber, div.MsoListNumber
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2, li.MsoList2, div.MsoList2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3, li.MsoList3, div.MsoList3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4, li.MsoList4, div.MsoList4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5, li.MsoList5, div.MsoList5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3, li.MsoListBullet3, div.MsoListBullet3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4, li.MsoListBullet4, div.MsoListBullet4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5, li.MsoListBullet5, div.MsoListBullet5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2, li.MsoListNumber2, div.MsoListNumber2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3, li.MsoListNumber3, div.MsoListNumber3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4, li.MsoListNumber4, div.MsoListNumber4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5, li.MsoListNumber5, div.MsoListNumber5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{mso-style-link:"Title Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:15.0pt;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:26.0pt;
	font-family:"Cambria",serif;
	color:#17365D;
	letter-spacing:.25pt;}
p.MsoTitleCxSpFirst, li.MsoTitleCxSpFirst, div.MsoTitleCxSpFirst
	{mso-style-link:"Title Char";
	margin:0in;
	border:none;
	padding:0in;
	font-size:26.0pt;
	font-family:"Cambria",serif;
	color:#17365D;
	letter-spacing:.25pt;}
p.MsoTitleCxSpMiddle, li.MsoTitleCxSpMiddle, div.MsoTitleCxSpMiddle
	{mso-style-link:"Title Char";
	margin:0in;
	border:none;
	padding:0in;
	font-size:26.0pt;
	font-family:"Cambria",serif;
	color:#17365D;
	letter-spacing:.25pt;}
p.MsoTitleCxSpLast, li.MsoTitleCxSpLast, div.MsoTitleCxSpLast
	{mso-style-link:"Title Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:15.0pt;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:26.0pt;
	font-family:"Cambria",serif;
	color:#17365D;
	letter-spacing:.25pt;}
p.MsoClosing, li.MsoClosing, div.MsoClosing
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:3.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoSignature, li.MsoSignature, div.MsoSignature
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:3.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-link:"Body Text Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue, li.MsoListContinue, div.MsoListContinue
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2, li.MsoListContinue2, div.MsoListContinue2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3, li.MsoListContinue3, div.MsoListContinue3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.75in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4, li.MsoListContinue4, div.MsoListContinue4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5, li.MsoListContinue5, div.MsoListContinue5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMessageHeader, li.MsoMessageHeader, div.MsoMessageHeader
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.75in;
	background:#CCCCCC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.MsoSalutation, li.MsoSalutation, div.MsoSalutation
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoDate, li.MsoDate, div.MsoDate
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent, li.MsoBodyTextFirstIndent, div.MsoBodyTextFirstIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:10.5pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent2, li.MsoBodyTextFirstIndent2, div.MsoBodyTextFirstIndent2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	text-indent:10.5pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNoteHeading, li.MsoNoteHeading, div.MsoNoteHeading
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:200%;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	line-height:200%;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0in;
	margin-right:1.0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
a:link, span.MsoHyperlink
	{font-family:"Times New Roman",serif;
	color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-style-link:"Document Map Char";
	margin:0in;
	background:navy;
	font-size:10.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{mso-style-link:"Plain Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.MsoAutoSig, li.MsoAutoSig, div.MsoAutoSig
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
address
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
pre
	{margin:0in;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MediumShading1-Accent21, li.MediumShading1-Accent21, div.MediumShading1-Accent21
	{mso-style-name:"Medium Shading 1 - Accent 21";
	margin:0in;
	font-size:11.0pt;
	font-family:"Minion",serif;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-link:"Heading 2";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-link:"Heading 4";
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.Heading5Char
	{mso-style-name:"Heading 5 Char";
	mso-style-link:"Heading 5";
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.Heading6Char
	{mso-style-name:"Heading 6 Char";
	mso-style-link:"Heading 6";
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.Heading7Char
	{mso-style-name:"Heading 7 Char";
	mso-style-link:"Heading 7";
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.Heading8Char
	{mso-style-name:"Heading 8 Char";
	mso-style-link:"Heading 8";
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.Heading9Char
	{mso-style-name:"Heading 9 Char";
	mso-style-link:"Heading 9";
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.TitleChar
	{mso-style-name:"Title Char";
	mso-style-link:Title;
	font-family:"Cambria",serif;
	color:#17365D;
	letter-spacing:.25pt;}
p.ColorfulShading-Accent31, li.ColorfulShading-Accent31, div.ColorfulShading-Accent31
	{mso-style-name:"Colorful Shading - Accent 31";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.ColorfulShading-Accent31CxSpFirst, li.ColorfulShading-Accent31CxSpFirst, div.ColorfulShading-Accent31CxSpFirst
	{mso-style-name:"Colorful Shading - Accent 31CxSpFirst";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.ColorfulShading-Accent31CxSpMiddle, li.ColorfulShading-Accent31CxSpMiddle, div.ColorfulShading-Accent31CxSpMiddle
	{mso-style-name:"Colorful Shading - Accent 31CxSpMiddle";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.ColorfulShading-Accent31CxSpLast, li.ColorfulShading-Accent31CxSpLast, div.ColorfulShading-Accent31CxSpLast
	{mso-style-name:"Colorful Shading - Accent 31CxSpLast";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.BookTitle1
	{mso-style-name:"Book Title1";
	font-variant:small-caps;
	letter-spacing:.25pt;
	font-weight:bold;}
span.IntenseReference1
	{mso-style-name:"Intense Reference1";
	font-variant:small-caps;
	color:#C0504D;
	letter-spacing:.25pt;
	font-weight:bold;
	text-decoration:underline;}
span.SubtleReference1
	{mso-style-name:"Subtle Reference1";
	font-variant:small-caps;
	color:#C0504D;
	text-decoration:underline;}
p.ColorfulGrid-Accent31, li.ColorfulGrid-Accent31, div.ColorfulGrid-Accent31
	{mso-style-name:"Colorful Grid - Accent 31";
	mso-style-link:"Colorful Grid - Accent 3 Char";
	margin-top:10.0pt;
	margin-right:.65in;
	margin-bottom:14.0pt;
	margin-left:.65in;
	border:none;
	padding:0in;
	font-size:10.0pt;
	font-family:"Minion",serif;
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
span.ColorfulGrid-Accent3Char
	{mso-style-name:"Colorful Grid - Accent 3 Char";
	mso-style-link:"Colorful Grid - Accent 31";
	font-family:"Minion",serif;
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
p.ColorfulList-Accent31, li.ColorfulList-Accent31, div.ColorfulList-Accent31
	{mso-style-name:"Colorful List - Accent 31";
	mso-style-link:"Colorful List - Accent 3 Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Minion",serif;
	color:black;
	font-style:italic;}
span.ColorfulList-Accent3Char
	{mso-style-name:"Colorful List - Accent 3 Char";
	mso-style-link:"Colorful List - Accent 31";
	font-family:"Minion",serif;
	color:black;
	font-style:italic;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;
	font-family:"Arial",sans-serif;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;
	font-family:"Times New Roman",serif;}
p.MemoHeaderStyle, li.MemoHeaderStyle, div.MemoHeaderStyle
	{mso-style-name:MemoHeaderStyle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.9pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BodyTextChar
	{mso-style-name:"Body Text Char";
	mso-style-link:"Body Text";
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	mso-style-link:"Comment Text";
	font-family:"Times New Roman",serif;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Tahoma",sans-serif;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.DraftingNotesAgency, li.DraftingNotesAgency, div.DraftingNotesAgency
	{mso-style-name:"Drafting Notes \(Agency\)";
	mso-style-link:"Drafting Notes \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
span.DraftingNotesAgencyChar
	{mso-style-name:"Drafting Notes \(Agency\) Char";
	mso-style-link:"Drafting Notes \(Agency\)";
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;}
p.TableheadingrowsAgency, li.TableheadingrowsAgency, div.TableheadingrowsAgency
	{mso-style-name:"Table heading rows \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	margin:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Paragraph, li.Paragraph, div.Paragraph
	{mso-style-name:Paragraph;
	mso-style-link:"Paragraph Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.5pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
span.ParagraphChar
	{mso-style-name:"Paragraph Char";
	mso-style-link:Paragraph;
	font-family:"Arial",sans-serif;}
p.TextTi12, li.TextTi12, div.TextTi12
	{mso-style-name:"Text\:Ti12";
	mso-style-link:"Text\:Ti12 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.5pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	line-height:14.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.TextTi12Char
	{mso-style-name:"Text\:Ti12 Char";
	mso-style-link:"Text\:Ti12";
	font-family:"Times New Roman",serif;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.Korrektur2, li.Korrektur2, div.Korrektur2
	{mso-style-name:Korrektur2;
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.PlainTextChar
	{mso-style-name:"Plain Text Char";
	mso-style-link:"Plain Text";
	font-family:"Arial",sans-serif;}
span.apple-converted-space
	{mso-style-name:apple-converted-space;}
p.Annex, li.Annex, div.Annex
	{mso-style-name:Annex;
	margin:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Description, li.Description, div.Description
	{mso-style-name:Description;
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.HangingIndent, li.HangingIndent, div.HangingIndent
	{mso-style-name:HangingIndent;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.AnnexHeading, li.AnnexHeading, div.AnnexHeading
	{mso-style-name:"Annex Heading";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Guideline, li.Guideline, div.Guideline
	{mso-style-name:Guideline;
	mso-style-link:"Guideline Tegn";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.GuidelineTegn
	{mso-style-name:"Guideline Tegn";
	mso-style-link:Guideline;
	font-family:"Verdana",sans-serif;}
p.No-numheading5Agency, li.No-numheading5Agency, div.No-numheading5Agency
	{mso-style-name:"No-num heading 5 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.paragraph0, li.paragraph0, div.paragraph0
	{mso-style-name:paragraph;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.DarkList-Accent31, li.DarkList-Accent31, div.DarkList-Accent31
	{mso-style-name:"Dark List - Accent 31";
	margin:0in;
	font-size:11.0pt;
	font-family:"Minion",serif;}
p.HangingIndent0, li.HangingIndent0, div.HangingIndent0
	{mso-style-name:"Hanging Indent";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.SAS8, li.SAS8, div.SAS8
	{mso-style-name:"SAS 8";
	mso-style-link:"SAS 8 Char";
	margin:0in;
	line-height:7.5pt;
	font-size:8.0pt;
	font-family:"Courier New";
	letter-spacing:-.5pt;}
span.SAS8Char
	{mso-style-name:"SAS 8 Char";
	mso-style-link:"SAS 8";
	font-family:"Courier New";
	letter-spacing:-.5pt;}
span.No-numheading3AgencyChar
	{mso-style-name:"No-num heading 3 \(Agency\) Char";
	mso-style-link:"No-num heading 3 \(Agency\)";
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.No-numheading3Agency, li.No-numheading3Agency, div.No-numheading3Agency
	{mso-style-name:"No-num heading 3 \(Agency\)";
	mso-style-link:"No-num heading 3 \(Agency\) Char";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.LightList-Accent31, li.LightList-Accent31, div.LightList-Accent31
	{mso-style-name:"Light List - Accent 31";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MediumList2-Accent23, li.MediumList2-Accent23, div.MediumList2-Accent23
	{mso-style-name:"Medium List 2 - Accent 23";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MediumShading1-Accent11, li.MediumShading1-Accent11, div.MediumShading1-Accent11
	{mso-style-name:"Medium Shading 1 - Accent 11";
	margin:0in;
	font-size:11.0pt;
	font-family:"Minion",serif;}
p.MediumGrid1-Accent21, li.MediumGrid1-Accent21, div.MediumGrid1-Accent21
	{mso-style-name:"Medium Grid 1 - Accent 21";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MediumGrid1-Accent21CxSpFirst, li.MediumGrid1-Accent21CxSpFirst, div.MediumGrid1-Accent21CxSpFirst
	{mso-style-name:"Medium Grid 1 - Accent 21CxSpFirst";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MediumGrid1-Accent21CxSpMiddle, li.MediumGrid1-Accent21CxSpMiddle, div.MediumGrid1-Accent21CxSpMiddle
	{mso-style-name:"Medium Grid 1 - Accent 21CxSpMiddle";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MediumGrid1-Accent21CxSpLast, li.MediumGrid1-Accent21CxSpLast, div.MediumGrid1-Accent21CxSpLast
	{mso-style-name:"Medium Grid 1 - Accent 21CxSpLast";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MediumGrid3-Accent21, li.MediumGrid3-Accent21, div.MediumGrid3-Accent21
	{mso-style-name:"Medium Grid 3 - Accent 21";
	margin-top:10.0pt;
	margin-right:.65in;
	margin-bottom:14.0pt;
	margin-left:.65in;
	border:none;
	padding:0in;
	font-size:10.0pt;
	font-family:"Minion",serif;
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
p.MediumGrid2-Accent21, li.MediumGrid2-Accent21, div.MediumGrid2-Accent21
	{mso-style-name:"Medium Grid 2 - Accent 21";
	margin:0in;
	font-size:10.0pt;
	font-family:"Minion",serif;
	color:black;
	font-style:italic;}
p.Korrektur1, li.Korrektur1, div.Korrektur1
	{mso-style-name:Korrektur1;
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MediumList2-Accent21, li.MediumList2-Accent21, div.MediumList2-Accent21
	{mso-style-name:"Medium List 2 - Accent 21";
	margin:0in;
	font-size:11.0pt;
	font-family:"Minion",serif;}
span.DocumentMapChar
	{mso-style-name:"Document Map Char";
	mso-style-link:"Document Map";
	font-family:"Tahoma",sans-serif;
	background:navy;}
p.MediumList2-Accent22, li.MediumList2-Accent22, div.MediumList2-Accent22
	{mso-style-name:"Medium List 2 - Accent 22";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.aqj
	{mso-style-name:aqj;}
p.AppTitle, li.AppTitle, div.AppTitle
	{mso-style-name:"App Title";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	text-align:center;
	line-height:14.0pt;
	page-break-before:always;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.AppContd, li.AppContd, div.AppContd
	{mso-style-name:"App Contd";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	text-align:center;
	line-height:14.0pt;
	page-break-before:always;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.FigureTitle, li.FigureTitle, div.FigureTitle
	{mso-style-name:"Figure Title";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.8in;
	text-indent:-.8in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.AppFigureTitle, li.AppFigureTitle, div.AppFigureTitle
	{mso-style-name:"App Figure Title";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.8in;
	text-indent:-.8in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.AppHeading1, li.AppHeading1, div.AppHeading1
	{mso-style-name:"App Heading 1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:15.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;
	text-decoration:underline;}
p.AppHeading2, li.AppHeading2, div.AppHeading2
	{mso-style-name:"App Heading 2";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.AppHeading3, li.AppHeading3, div.AppHeading3
	{mso-style-name:"App Heading 3";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	text-decoration:underline;}
p.AppHeading4, li.AppHeading4, div.AppHeading4
	{mso-style-name:"App Heading 4";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:1.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.TableTitle, li.TableTitle, div.TableTitle
	{mso-style-name:"Table Title";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.8in;
	text-indent:-.8in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.AppTableTitle, li.AppTableTitle, div.AppTableTitle
	{mso-style-name:"App Table Title";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.8in;
	text-indent:-.8in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.BibliXRef, li.BibliXRef, div.BibliXRef
	{mso-style-name:BibliXRef;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.5pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.CNFigureTitle, li.CNFigureTitle, div.CNFigureTitle
	{mso-style-name:"CN Figure Title";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:1.75in;
	text-indent:-1.75in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.TabFigContd, li.TabFigContd, div.TabFigContd
	{mso-style-name:"TabFig Contd";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.8in;
	text-indent:-.8in;
	line-height:14.0pt;
	page-break-before:always;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.CNTabFigContd, li.CNTabFigContd, div.CNTabFigContd
	{mso-style-name:"CN TabFig Contd";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:1.75in;
	text-indent:-1.75in;
	line-height:14.0pt;
	page-break-before:always;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.CNTableTitle, li.CNTableTitle, div.CNTableTitle
	{mso-style-name:"CN Table Title";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:1.75in;
	text-indent:-1.75in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.COSP, li.COSP, div.COSP
	{mso-style-name:COSP;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:12.0pt;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.FigureHolder, li.FigureHolder, div.FigureHolder
	{mso-style-name:"Figure Holder";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:center;
	line-height:12.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.FormText, li.FormText, div.FormText
	{mso-style-name:"Form Text";
	margin-top:1.0pt;
	margin-right:0in;
	margin-bottom:1.0pt;
	margin-left:0in;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;}
p.Heading1NoNum, li.Heading1NoNum, div.Heading1NoNum
	{mso-style-name:"Heading 1 NoNum";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:15.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;
	text-decoration:underline;}
p.Heading2NoNum, li.Heading2NoNum, div.Heading2NoNum
	{mso-style-name:"Heading 2 NoNum";
	margin:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.Heading3NoNum, li.Heading3NoNum, div.Heading3NoNum
	{mso-style-name:"Heading 3 NoNum";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	text-decoration:underline;}
p.Heading4NoNum, li.Heading4NoNum, div.Heading4NoNum
	{mso-style-name:"Heading 4 NoNum";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:1.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Heading5NoNum, li.Heading5NoNum, div.Heading5NoNum
	{mso-style-name:"Heading 5 NoNum";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:1.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.HeadingCentNoNum, li.HeadingCentNoNum, div.HeadingCentNoNum
	{mso-style-name:"Heading CentNoNum";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:15.0pt;
	margin-left:0in;
	text-align:center;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.HeadingDoc, li.HeadingDoc, div.HeadingDoc
	{mso-style-name:"Heading Doc";
	margin-top:5.65pt;
	margin-right:0in;
	margin-bottom:2.85pt;
	margin-left:0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.HiddenChar
	{mso-style-name:"Hidden\:Char";
	font-family:"Arial",sans-serif;
	color:green;
	display:none;
	font-style:italic;
	text-decoration:underline;
	vertical-align:baseline;}
p.HiddenPara, li.HiddenPara, div.HiddenPara
	{mso-style-name:"Hidden\:Para";
	mso-style-link:"Hidden\:Para Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	color:green;
	display:none;
	font-weight:bold;
	text-decoration:underline;}
p.ListAlpha, li.ListAlpha, div.ListAlpha
	{mso-style-name:"List Alpha";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:.3in;
	text-indent:-.3in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.ListDash, li.ListDash, div.ListDash
	{mso-style-name:"List Dash";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:.3in;
	text-indent:-.3in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.ListofTFA, li.ListofTFA, div.ListofTFA
	{mso-style-name:"List of TFA";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:1.3in;
	text-indent:-1.3in;
	line-height:16.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.ListText, li.ListText, div.ListText
	{mso-style-name:"List Text";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:.3in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.ParagraphList, li.ParagraphList, div.ParagraphList
	{mso-style-name:"Paragraph List";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:0in;
	line-height:15.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.ParagraphSpace, li.ParagraphSpace, div.ParagraphSpace
	{mso-style-name:"Paragraph Space";
	margin:0in;
	line-height:6.0pt;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.Reference, li.Reference, div.Reference
	{mso-style-name:Reference;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.5pt;
	margin-left:.3in;
	text-indent:-.3in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.SAS10, li.SAS10, div.SAS10
	{mso-style-name:"SAS 10";
	margin:0in;
	line-height:9.5pt;
	font-size:10.0pt;
	font-family:"Courier New";
	letter-spacing:-.7pt;}
p.SynopsisBullet, li.SynopsisBullet, div.SynopsisBullet
	{mso-style-name:"Synopsis Bullet";
	margin-top:0in;
	margin-right:.05in;
	margin-bottom:4.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:11.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.SynopsisHead1, li.SynopsisHead1, div.SynopsisHead1
	{mso-style-name:"Synopsis Head 1";
	margin-top:6.0pt;
	margin-right:.05in;
	margin-bottom:2.0pt;
	margin-left:.05in;
	line-height:11.0pt;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	text-decoration:underline;}
p.SynopsisHead2, li.SynopsisHead2, div.SynopsisHead2
	{mso-style-name:"Synopsis Head 2";
	margin-top:4.0pt;
	margin-right:.05in;
	margin-bottom:2.0pt;
	margin-left:.05in;
	line-height:11.0pt;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.SynopsisText, li.SynopsisText, div.SynopsisText
	{mso-style-name:"Synopsis Text";
	margin-top:0in;
	margin-right:.05in;
	margin-bottom:3.0pt;
	margin-left:.05in;
	line-height:11.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.SynopsisSpace, li.SynopsisSpace, div.SynopsisSpace
	{mso-style-name:"Synopsis Space";
	margin-top:0in;
	margin-right:.05in;
	margin-bottom:3.0pt;
	margin-left:.05in;
	line-height:6.0pt;
	font-size:6.0pt;
	font-family:"Times New Roman",serif;}
p.TabFigNote, li.TabFigNote, div.TabFigNote
	{mso-style-name:"TabFig Note";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.45pt;
	line-height:12.0pt;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.TabFigFooter, li.TabFigFooter, div.TabFigFooter
	{mso-style-name:"TabFig Footer";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:12.25pt;
	text-indent:-.15in;
	line-height:12.0pt;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.TableCell10Left, li.TableCell10Left, div.TableCell10Left
	{mso-style-name:"Table Cell 10 Left";
	margin-top:2.5pt;
	margin-right:0in;
	margin-bottom:2.5pt;
	margin-left:0in;
	line-height:12.0pt;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.TableCell10Center, li.TableCell10Center, div.TableCell10Center
	{mso-style-name:"Table Cell 10 Center";
	margin-top:2.5pt;
	margin-right:0in;
	margin-bottom:2.5pt;
	margin-left:0in;
	text-align:center;
	line-height:12.0pt;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.TableCell12Left, li.TableCell12Left, div.TableCell12Left
	{mso-style-name:"Table Cell 12 Left";
	margin-top:2.5pt;
	margin-right:0in;
	margin-bottom:2.5pt;
	margin-left:0in;
	line-height:12.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.TableCell12Center, li.TableCell12Center, div.TableCell12Center
	{mso-style-name:"Table Cell 12 Center";
	margin-top:2.5pt;
	margin-right:0in;
	margin-bottom:2.5pt;
	margin-left:0in;
	text-align:center;
	line-height:12.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.TableofCNFigures, li.TableofCNFigures, div.TableofCNFigures
	{mso-style-name:"Table of CN Figures";
	margin-top:0in;
	margin-right:84.75pt;
	margin-bottom:0in;
	margin-left:135.8pt;
	text-indent:-135.8pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.TOC, li.TOC, div.TOC
	{mso-style-name:TOC;
	margin-top:19.85pt;
	margin-right:0in;
	margin-bottom:11.35pt;
	margin-left:0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.TOC1XHeadSub, li.TOC1XHeadSub, div.TOC1XHeadSub
	{mso-style-name:"TOC 1 XHeadSub";
	margin-top:11.35pt;
	margin-right:1.0in;
	margin-bottom:5.65pt;
	margin-left:1.0in;
	text-indent:-1.0in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.TOC2XHeadSub, li.TOC2XHeadSub, div.TOC2XHeadSub
	{mso-style-name:"TOC 2 XHeadSub";
	margin-top:0in;
	margin-right:1.0in;
	margin-bottom:5.65pt;
	margin-left:.25in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.TOCHead, li.TOCHead, div.TOCHead
	{mso-style-name:"TOC Head";
	margin-top:19.85pt;
	margin-right:0in;
	margin-bottom:11.35pt;
	margin-left:0in;
	line-height:14.0pt;
	page-break-before:always;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.XHead, li.XHead, div.XHead
	{mso-style-name:"X Head";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:70.55pt;
	text-indent:-70.55pt;
	line-height:16.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	text-decoration:underline;}
p.XHead125, li.XHead125, div.XHead125
	{mso-style-name:"X Head 1\.25";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:1.25in;
	text-indent:-1.25in;
	line-height:16.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	text-decoration:underline;}
p.XHead150, li.XHead150, div.XHead150
	{mso-style-name:"X Head 1\.50";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:1.5in;
	text-indent:-1.5in;
	line-height:16.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	text-decoration:underline;}
p.XHead175, li.XHead175, div.XHead175
	{mso-style-name:"X Head 1\.75";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:1.75in;
	text-indent:-1.75in;
	line-height:16.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	text-decoration:underline;}
p.XHeadSub, li.XHeadSub, div.XHeadSub
	{mso-style-name:XHeadSub;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.55pt;
	text-indent:-70.55pt;
	line-height:16.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.xInstrux, li.xInstrux, div.xInstrux
	{mso-style-name:xInstrux;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	color:red;
	font-weight:bold;}
span.HiddenParaChar
	{mso-style-name:"Hidden\:Para Char";
	mso-style-link:"Hidden\:Para";
	font-family:"Arial",sans-serif;
	color:green;
	display:none;
	font-weight:bold;
	text-decoration:underline;}
p.HeadingAppFiTitle, li.HeadingAppFiTitle, div.HeadingAppFiTitle
	{mso-style-name:"Heading App FiTitle";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:2.85pt;
	margin-left:1.1in;
	text-indent:-1.1in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:#080808;
	font-weight:bold;}
p.HeadingAppPhTitle, li.HeadingAppPhTitle, div.HeadingAppPhTitle
	{mso-style-name:"Heading App PhTitle";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:2.85pt;
	margin-left:1.1in;
	text-indent:-1.1in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:#1C1C1C;
	font-weight:bold;}
p.HeadingFigureFiTitle, li.HeadingFigureFiTitle, div.HeadingFigureFiTitle
	{mso-style-name:"Heading Figure FiTitle";
	margin-top:5.65pt;
	margin-right:0in;
	margin-bottom:2.85pt;
	margin-left:.8in;
	text-indent:-.8in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.HeadingFigurePhTitle, li.HeadingFigurePhTitle, div.HeadingFigurePhTitle
	{mso-style-name:"Heading Figure PhTitle";
	margin-top:5.65pt;
	margin-right:0in;
	margin-bottom:2.85pt;
	margin-left:.8in;
	text-indent:-.8in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.HeadingTableFiTitle, li.HeadingTableFiTitle, div.HeadingTableFiTitle
	{mso-style-name:"Heading Table FiTitle";
	margin-top:5.65pt;
	margin-right:0in;
	margin-bottom:2.85pt;
	margin-left:.8in;
	text-indent:-.8in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:#111111;
	font-weight:bold;}
p.HeadingTablePhTitle, li.HeadingTablePhTitle, div.HeadingTablePhTitle
	{mso-style-name:"Heading Table PhTitle";
	margin-top:5.65pt;
	margin-right:0in;
	margin-bottom:2.85pt;
	margin-left:.8in;
	text-indent:-.8in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:#292929;
	font-weight:bold;}
span.CommentTextChar2
	{mso-style-name:"Comment Text Char2";}
span.m9220114500512215066m-6500666881044775903gmail-msodel
	{mso-style-name:m_9220114500512215066m_-6500666881044775903gmail-msodel;}
span.m9220114500512215066m-6500666881044775903gmail-msoins
	{mso-style-name:m_9220114500512215066m_-6500666881044775903gmail-msoins;}
span.msoIns
	{mso-style-name:"";
	text-decoration:underline;
	color:teal;}
span.msoDel
	{mso-style-name:"";
	text-decoration:line-through;
	color:red;}
.MsoChpDefault
	{font-size:10.0pt;
	font-family:"Calibri",sans-serif;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal align=center style='text-align:center'><b><span
style='font-size:10.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span
style='font-size:10.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span
style='font-size:10.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>ANNEX I</b></p>

<p class=MsoNormal align=center style='text-align:center'>&nbsp;</p>

<p class=Annex>SUMMARY OF PRODUCT CHARACTERISTICS</p>

<b><span style='font-size:10.0pt;font-family:"Times New Roman",serif;
color:green'><br clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Perjeta 420&nbsp;mg concentrate for
solution for infusion</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>2. QUALITATIVE AND QUANTITATIVE
COMPOSITION</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>One 14&nbsp;ml vial of concentrate contains
420&nbsp;mg of pertuzumab at a concentration of 30&nbsp;mg/ml.</span></p>

<p class=MsoNormal><span lang=EN-GB>After dilution, one ml of solution contains
approximately 3.02 mg of pertuzumab for the initial dose and approximately 1.59
mg of pertuzumab for the maintenance dose (see section 6.6).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Pertuzumab is a humanised IgG1 monoclonal
antibody produced in mammalian (Chinese hamster ovary) cells by recombinant DNA
technology.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For the full list of excipients, see
section 6.1.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>3. PHARMACEUTICAL FORM</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Concentrate for solution for infusion.</span></p>

<p class=MsoNormal><span lang=EN-GB>Clear to slightly opalescent, colourless to
pale yellow, liquid.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='text-transform:uppercase'>4. </span></b><b><span
lang=EN-GB>CLINICAL PARTICULARS</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>4.1 Therapeutic indications</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Early breast cancer</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Perjeta is indicated for use in combination
with trastuzumab and chemotherapy in:</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>the neoadjuvant treatment of adult patients with HER2-positive,
locally advanced, inflammatory, or early stage breast cancer at high risk of
recurrence (see section 5.1)</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>the adjuvant treatment of adult patients with HER2-positive early
breast cancer at high risk of recurrence (see section 5.1)</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Metastatic breast cancer</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Perjeta is indicated for use in combination
with trastuzumab and docetaxel in adult patients with HER2-positive metastatic
or locally recurrent unresectable breast cancer,</span><b><i><span lang=EN-GB
style='font-family:"Arial",sans-serif'> </span></i></b><span lang=EN-GB>who
have not received previous anti-HER2 therapy or chemotherapy for their
metastatic disease.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>4.2 Posology and method of
administration</span></b></p>

<p class=MsoNormal><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal><span lang=EN-GB>Perjeta should only be initiated under the
supervision of a physician experienced in the administration of anti-cancer
agents. Perjeta should be administered by a healthcare professional prepared to
manage anaphylaxis and </span><span lang=EN-GB>in an environment where full
resuscitation facilities are immediately available</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients treated with Perjeta must have
HER2-positive tumour status, defined as a score of 3+ by immunohistochemistry
(IHC) and/or a ratio of &#8805;&nbsp;2.0 by in situ hybridisation (ISH)
assessed by a validated test.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>To ensure accurate and reproducible
results, the testing must be performed in a specialised laboratory, which can
ensure validation of the testing procedures. For full instructions on assay
performance and interpretation please refer to the package leaflets of
validated HER2 testing assays.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>The recommended initial loading dose of pertuzumab
is 840&nbsp;mg administered as a 60 minute intravenous infusion, followed every
3 weeks thereafter by a maintenance dose of 420&nbsp;mg administered over a
period of 30 to 60 minutes. An observation period of 30 - 60 minutes is
recommended after completion of each infusion. The observation period should
be completed prior to any subsequent infusion of trastuzumab or chemotherapy
(see section 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Perjeta and trastuzumab should be
administered sequentially and not mixed in the same infusion bag. Perjeta and
trastuzumab can be given in any order. When administered with Perjeta the </span></p>

<p class=MsoNormal><span lang=EN-GB>recommendation is to follow a 3 weekly
schedule for trastuzumab administered as either:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> an IV
infusion with an initial loading dose of trastuzumab 8&nbsp;mg/kg body weight
followed every 3 weeks thereafter by a maintenance dose of 6&nbsp;mg/kg body
weight</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB>or </span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> a fixed
subcutaneous dose of trastuzumab by injection (600&nbsp;mg) every 3 weeks irrespective
of the patients body weight.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In patients receiving a taxane, Perjeta and
trastuzumab should be administered prior to the taxane. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>When administered with Perjeta, docetaxel can be started at
75 mg/m2, and subsequently escalated to 100 mg/m2 depending on the chosen
regimen and tolerability of the initial dose. Alternatively, docetaxel can be
given at 100 mg/m2 on a 3 weekly schedule from the start, again depending on
the chosen regimen. If a carboplatin-based regimen is used, the recommended dose
for docetaxel is 75 mg/m2 throughout (no dose escalation). <span lang=EN-GB>When
administered with Perjeta in the adjuvant setting, the recommended dose of
paclitaxel is 80 mg/m2 once weekly for 12 weekly cycles.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-CARRIBEAN>In patients receiving an anthracycline-based
regimen, Perjeta and trastuzumab should be administered following completion of
the entire anthracycline regimen (see section 4.4). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Metastatic breast cancer</span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Perjeta should be administered in
combination with trastuzumab and docetaxel . Treatment with Perjeta and
trastuzumab may continue until disease progression or unmanageable toxicity
even if treatment with docetaxel is discontinued.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Early breast cancer</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>In the neoadjuvant setting, Perjeta should
be administered for 3 to 6 cycles in combination with </span><span lang=EN-GB>trastuzumab
and chemotherapy, as part of a complete treatment regimen for early breast
cancer (see section 5.1). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>In the adjuvant setting, Perjeta should be administered in
combination with trastuzumab for a total of one year (up to 18 cycles or until
disease recurrence, or unmanageable toxicity, whichever occurs first) as part
of a complete regimen for early breast cancer and regardless of the timing of
surgery. Treatment should include standard anthracycline- and/or taxane-based
chemotherapy. Perjeta and trastuzumab should start on Day 1 of the first
taxane-containing cycle and should continue even if chemotherapy is
discontinued<span lang=EN-GB>. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Delayed
or missed doses</span></i></p>

<p class=MsoNormal><span lang=EN-CARRIBEAN style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-CARRIBEAN style='color:black'>For
recommendations on delayed or missed doses, please refer to Table 1 below.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in;page-break-after:
avoid'><b><span lang=EN-GB>Table 1 Recommendations regarding delayed or
missed doses</span></b></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=137 rowspan=2 valign=top style='width:103.05pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b>Time between two
  sequential infusions</b></p>
  </td>
  <td width=168 rowspan=2 valign=top style='width:126.1pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b>Perjeta </b></p>
  </td>
  <td width=314 colspan=2 valign=top style='width:235.2pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b>trastuzumab</b></p>
  </td>
 </tr>
 <tr>
  <td width=165 valign=top style='width:123.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b>IV</b></p>
  </td>
  <td width=149 valign=top style='width:111.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b>SC</b></p>
  </td>
 </tr>
 <tr>
  <td width=137 valign=top style='width:103.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>&lt; 6 weeks</p>
  </td>
  <td width=168 valign=top style='width:126.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>The 420 mg dose of
  pertuzumab should be administered as soon as possible. Do not wait until the
  next planned dose. Thereafter, revert to the original planned schedule.</p>
  </td>
  <td width=165 valign=top style='width:123.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>The 6&nbsp;mg/kg dose of trastuzumab
  IV should be administered as soon as possible. Do not wait until the next
  planned dose. Thereafter, revert to the original planned schedule.</p>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=149 rowspan=2 valign=top style='width:111.65pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>The fixed dose of 600mg
  trastuzumab SC should be administered as soon as possible. </p>
  <p class=MsoNormal style='page-break-after:avoid'>Do not wait until the next
  planned dose.</p>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=137 valign=top style='width:103.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=ZH-CN
  style='font-family:SimSun'>&#8805;</span> 6 weeks</p>
  </td>
  <td width=168 valign=top style='width:126.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>The 840 mg loading dose of
  pertuzumab should be re-administered&nbsp;as a 60 minute infusion, followed
  by a maintenance dose of 420 mg IV administered every 3 weeks thereafter.</p>
  </td>
  <td width=165 valign=top style='width:123.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>The&nbsp;loading dose of
  8&nbsp;mg/kg of trastuzumab IV should be re- administered&nbsp;over
  approximately 90&nbsp;minutes, followed by a maintenance dose of 6&nbsp;mg/kg
  IV&nbsp;administered every 3 weeks thereafter.</p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Dose modification</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Dose reductions are not recommended for Perjeta
or trastuzumab. For details regarding trastuzumab, please refer to the summary
of product characteristics (SmPC). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Patients may continue
therapy during periods of reversible chemotherapy-induced myelosuppression but
they should be monitored carefully for complications of neutropenia during this
time. </span><span lang=EN-GB>For docetaxel </span><span lang=EN-GB>and other
chemotherapy </span><span lang=EN-GB>dose modifications, see </span><span
lang=EN-GB>relevant</span><span lang=EN-GB> SmPC.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If trastuzumab treatment is discontinued,
treatment with Perjeta should be discontinued. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Left ventricular dysfunction </span></i></p>

<p class=MsoNormal><span lang=EN-GB>Perjeta and trastuzumab should be withheld
for at least 3 <span style='color:black'>weeks for </span></span><span
lang=EN-GB style='color:black'>any </span><span lang=EN-GB>signs and symptoms
suggestive of congestive heart failure. Perjeta should be discontinued if
symptomatic heart failure is confirmed (see section 4.4 for more details).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Patients with metastatic breast cancer</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Patients should have a pre-treatment left
ventricular ejection fraction (LVEF) of &#8805; 50%. Perjeta and trastuzumab
should be withheld for at least 3 weeks for:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> a drop in
LVEF to less than 40% </span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> a LVEF of
40%-45% associated with a fall of &#8805;&nbsp;10% points below pre-treatment
value.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Perjeta and trastuzumab may be resumed if
the LVEF has recovered to &gt;&nbsp;45%, or to 40-45% associated with a
difference of &lt;&nbsp;10% points below pre-treatment values. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Patients
with early breast cancer</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Patients
should have a pre-treatment LVEF of &#8805; 55% (&#8805; 50% after completion
of the anthracycline component of chemotherapy, if given). Perjeta and
trastuzumab should be withheld for at least 3 weeks for: </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt;page-break-after:
avoid'><span style='font-family:Symbol;color:black'></span><span lang=BG
style='color:black'> </span><span lang=EN-GB>a drop in LVEF to less than 50%
associated with a fall of &#8805; 10% points below pre-treatment values.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Perjeta and trastuzumab may be resumed if
the LVEF has recovered to &#8805;50% or to a difference of &lt;&nbsp;10% points
below pre-treatment values. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Elderly
patients</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'>No overall differences in efficacy
of Perjeta were observed in patients &#8805; 65 and &lt; 65 years of age. <span
lang=EN-GB>No dose adjustment is necessary in the elderly population &#8805;&nbsp;65
years of age. Limited data are available in patients &gt;&nbsp;75 years of age.
Please see section 4.8 for assessment of safety of Perjeta in elderly patients.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Renal impairment</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Dose adjustments of pertuzumab are not
needed in patients with mild or moderate renal impairment. No dose
recommendations can be made for patients with severe renal impairment because
of the limited pharmacokinetic data available (see section 5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Hepatic impairment</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The safety and efficacy of Perjeta have not
been studied in patients with hepatic impairment. No specific dose
recommendations can be made.</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Paediatric
population</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The safety and efficacy of Perjeta in
children and adolescents below 18 years of age have not been established.</span><span
lang=EN-GB> There is no relevant use of Perjeta in the paediatric population in
the indication of breast cancer.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='color:black'>Method of administration</span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Perjeta is administered intravenously by
infusion. It should not be administered as an intravenous push or bolus. For
instructions on dilution of Perjeta prior to administration, see sections 6.2
and 6.6.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For the initial dose, the recommended
infusion period is 60 minutes. If the first infusion is well tolerated,
subsequent infusions may be administered over a period of 30 minutes to 60
minutes (see section 4.4).</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Infusion
reactions</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The infusion rate may be slowed or
interrupted if the patient develops an infusion reaction (see section 4.8). The
infusion may be resumed when symptoms abate. Treatment including oxygen, beta
agonists, antihistamines, rapid i.v. fluids and antipyretics may also help
alleviate symptoms. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Hypersensitivity reactions/anaphylaxis </span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The infusion should be discontinued
immediately and permanently if the patient experiences a NCI-CTCAE Grade 4
reaction (anaphylaxis), </span><span lang=EN-GB>bronchospasm or acute
respiratory distress syndrome (see section 4.4).</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.3 Contraindications</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Hypersensitivity
to the active substance or to any of the excipients listed in section 6.1.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.4 Special
warnings and precautions for use</span></b><b><span lang=EN-GB> </span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Traceability</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In order to improve the traceability of
biological medicinal products, the name and batch number of the administered
product should be clearly recorded.</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><u><span lang=EN-GB>Left ventricular dysfunction (including
congestive heart failure)</span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Decreases in LVEF have been reported with
medicinal products that block HER2 activity, including Perjeta. The incidence
of symptomatic left ventricular systolic dysfunction (LVD) [congestive heart
failure] was higher in patients treated with Perjeta in combination with trastuzumab
and chemotherapy compared with trastuzumab and chemotherapy . Patients who have
received prior anthracyclines or prior radiotherapy to the chest area may be at
higher risk of LVEF declines. The majority of cases of symptomatic heart
failure reported in the adjuvant setting were in patients who received
anthracycline-based chemotherapy (see section 4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Perjeta</span><span lang=EN-GB> has not
been studied in patients with:&nbsp;a pre-treatment LVEF value of &lt;&nbsp;50%;
a prior history of congestive heart failure (CHF); LVEF declines to &lt;&nbsp;50%
during prior trastuzumab adjuvant therapy; or conditions that could impair left
ventricular function such as uncontrolled hypertension, recent myocardial
infarction, serious cardiac arrhythmia requiring treatment or a cumulative
prior anthracycline exposure to &gt;&nbsp;360&nbsp;mg/m<sup>2</sup> of
doxorubicin or its equivalent.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Assess LVEF prior to initiation of Perjeta
and at regular intervals during treatment </span><span lang=EN-GB>with Perjeta
(e.g. once during neoadjuvant treatment and every 12 weeks in the adjuvant or
metastatic setting) </span><span lang=EN-GB>to ensure that LVEF is within
normal limits. If the LVEF has declined as indicated in section 4.2 and has not
improved, or has declined further at the subsequent assessment, discontinuation
of Perjeta and trastuzumab should be strongly considered, unless the benefits
for the individual patient are deemed to outweigh the risks. </span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'><span
lang=EN-GB>Cardiac risk should be carefully considered and balanced against the
medical need of the individual patient before use of Perjeta with an anthracycline.
</span><span lang=EN-GB>Based on the pharmacological actions of <br>
HER2-targeted agents and anthracyclines, the risk of cardiac toxicity might be
expected to be higher with concomitant&nbsp;use of Perjeta and anthracyclines
than with sequential use. </span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Sequential use of Perjeta (in combination
with trastuzumab and a taxane) has been evaluated following the epirubicin or
doxorubicin component of many anthracycline-based regimens in the APHINITY and
BERENICE studies. However, only limited safety data are available on concurrent
use of Perjeta and an anthracycline. In the TRYPHAENA study, Perjeta was given concurrently
with epirubicin, as part of the FEC</span><span lang=EN-GB> </span>(5-fluorouracil,
epirubicin, cyclophosphamide) <span lang=EN-GB>regimen (see sections 4.8 and
5.1). Only chemotherapy-naive patients were treated and they received low
cumulative doses of epirubicin (up to 300 mg/m<sup>2</sup>). In this study,
cardiac safety was similar to that observed in patients given the same regimen but
with Perjeta administered sequentially (following FEC chemotherapy).</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><u><span lang=EN-GB>Infusion reactions</span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Perjeta
has been associated with infusion reactions, including events with a fatal
outcome (</span><span lang=EN-GB style='color:black'>see section 4.8</span><span
lang=EN-GB style='color:black'>). Close observation of the patient during and
for 60 minutes after the first infusion and during and for 30-60 minutes after
subsequent infusions of Perjeta is recommended. If a significant infusion</span><span
lang=EN-GB style='color:black'> </span><span lang=EN-GB style='color:black'>reaction
occurs, the infusion should be slowed down or interrupted and appropriate
medical therapies should be administered. Patients should be evaluated and
carefully monitored until complete resolution of signs and symptoms.</span><span
lang=EN-GB style='color:black'> Permanent discontinuation should be considered
in patients with severe infusion reactions. This clinical assessment should be
based on the severity of the preceding reaction and response to administered
treatment for the adverse reaction (see section 4.2).</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Hypersensitivity
reactions/anaphylaxis</span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Patients should be observed closely for
hypersensitivity reactions. Severe hypersensitivity, including anaphylaxis and
events with a fatal outcome, has been observed with Perjeta (see section 4.8).
Medicinal products to treat such reactions, as well as emergency equipment,
should be available for immediate use. Perjeta must be permanently discontinued
in case of NCI-CTCAE Grade 4 hypersensitivity reactions (anaphylaxis), bronchospasm
or acute respiratory distress syndrome (see section 4.2). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Febrile neutropenia</span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Patients treated with Perjeta, trastuzumab
and docetaxel are at increased risk of febrile neutropenia compared with
patients treated with placebo, trastuzumab and docetaxel, especially during the
first 3 cycles of treatment (see section 4.8). </span><span lang=EN-GB>In the
CLEOPATRA trial in metastatic breast cancer,</span><span lang=EN-GB> nadir
neutrophil counts were similar in Perjeta-treated and placebo-treated patients</span><span
lang=EN-GB>. The</span><span lang=EN-GB> higher incidence of febrile
neutropenia in Perjeta-treated patients </span><span lang=EN-GB>was</span><span
lang=EN-GB> associated with the higher incidence of mucositis and diarrhoea in
these patients. Symptomatic treatment for mucositis and diarrhoea should be
considered. </span><span lang=EN-GB>No</span><span lang=EN-GB> events of
febrile neutropenia were reported after cessation of docetaxel.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=ES>Diarrhoea</span></u></p>

<p class=MsoNormal><span lang=ES>&nbsp;</span></p>

<p class=MsoNormal><span lang=ES>Perjeta may elicit severe diarrhoea. </span><span
lang=EN-GB>Diarrhoea is most frequent during concurrent administration with
taxane therapy.</span> Elderly patients (<u>&gt;</u> 65 years) have a higher
risk of diarrhoea compared with younger patients (&lt;<u> </u>65 years). Treat
diarrhoea according to standard practice and guidelines. Early intervention
with loperamide, fluids and electrolyte replacement should be considered,
particularly in elderly patients, and in case of severe or prolonged
diarrhoea. <span lang=EN-GB>Interruption of treatment with pertuzumab should
be considered if no improvement in the patients condition is achieved. When
the diarrhoea is under control treatment with pertuzumab may be reinstated.</span></p>

<p class=MsoNormal><b><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></b></p>

<p class=MsoNormal><b><span lang=EN-GB>4.5 Interaction with other
medicinal products and other forms of interaction</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No pharmacokinetic (PK) interactions were
observed between </span><span lang=EN-GB>pertuzumab</span><span lang=EN-GB> and
trastuzumab, or between </span><span lang=EN-GB>pertuzumab</span><span
lang=EN-GB> and docetaxel in a sub-study of 37 patients in the randomised,
pivotal trial CLEOPATRA</span><span lang=EN-GB> in metastatic breast cancer</span><span
lang=EN-GB>. In addition, in the population PK analysis, no evidence of a
drug-drug interaction has been shown between </span><span lang=EN-GB>pertuzumab</span><span
lang=EN-GB> and trastuzumab </span><span lang=EN-GB>or</span><span lang=EN-GB>
between </span><span lang=EN-GB>pertuzumab</span><span lang=EN-GB> and
docetaxel</span><span lang=EN-GB>. This absence of drug-drug interaction was
confirmed by pharmacokinetic data from the NEOSPHERE and APHINITY studies</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Five studies evaluated the effects of </span><span
lang=EN-GB>pertuzumab</span><span lang=EN-GB> on the PK of co-administered
cytotoxic agents, docetaxel, paclitaxel, gemcitabine, capecitabine, carboplatin
and erlotinib. There was no evidence of any PK interaction between </span><span
lang=EN-GB>pertuzumab</span><span lang=EN-GB> and any of these agents. The PK
of </span><span lang=EN-GB>pertuzumab</span><span lang=EN-GB> in these studies was
comparable to those observed in single-agent studies.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.6 Fertility,
p</span></b><b><span lang=EN-GB>regnancy and lactation</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Contraception
</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Women of
childbearing potential should use effective contraception while receiving
Perjeta and for 6 months following the last dose of pertuzumab.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There is limited amount of data from the
use of pertuzumab in pregnant women. </span></p>

<p class=MsoNormal><span lang=EN-GB>Studies in animals have shown reproductive
toxicity (see section 5.3).</span></p>

<p class=MsoNormal><span lang=EN-GB>Perjeta is not recommended during pregnancy
and in women of childbearing potential not using contraception. </span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Breast-feeding</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Because human IgG is secreted in human milk
and the potential for absorption and harm to the infant is unknown, a decision
should be made to discontinue breast-feeding or to discontinue treatment,
taking into account the benefit of breast-feeding for the child and the benefit
of Perjeta therapy for the woman (see section 5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No specific fertility studies in animals
have been performed to evaluate the effect of </span><span lang=EN-GB>pertuzumab</span><span
lang=EN-GB>.</span><span lang=EN-GB> In repeated dose toxicity studies in
cynomolgus monkeys, no definitive conclusions could be drawn on the adverse
effect on male reproductive organs. </span><span lang=EN-GB>No adverse reactions
were observed in sexually mature female cynomolgus monkeys exposed to
pertuzumab (see section 5.3).</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.7 Effects
on ability to drive and use machines</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>On the basis
of reported adverse reactions, Perjeta has a minor influence on the ability to
drive or use machines. </span>Dizziness may occur during treatment with Perjeta
(see section&nbsp;4.8). <span lang=EN-GB>Patients experiencing infusion
reactions should be advised not to drive and use machines until symptoms abate.
</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>4.8 Undesirable effects</span></b><b><span
lang=EN-GB> </span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Summary of the safety profile</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The safety of Perjeta has been evaluated in
more than 6,000 patients in </span><span lang=EN-GB>Phase</span><span
lang=EN-GB> I, II, and III trials in patients with various malignancies and
predominantly treated with Perjeta in combination with other antineoplastic
agents. </span>Those studies included the pivotal trials CLEOPATRA (n=808),
NEOSPHERE (n=417), TRYPHAENA (n=225), and APHINITY (n=4804) [pooled in Table
2]. <span lang=EN-GB>The safety of Perjeta was generally consistent across
studies, although the incidence and most common adverse drug reactions (ADRs)
varied depending on whether Perjeta was administered as monotherapy or with
concomitant anti-neoplastic agents. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Tabulated
list of adverse reactions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Table 2 summarizes
the ADRs from the Perjeta-treated groups of the following pivotal clinical
trials:</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> CLEOPATRA,
in which Perjeta was given in combination with docetaxel and trastuzumab</span><span
lang=EN-GB> to patients with metastatic breast cancer (n=453)</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB style='color:black'>NEOSPHERE (n=309) and TRYPHAENA (n=218), in
which neoadjuvant Perjeta was given in combination with trastuzumab and
chemotherapy to patients with locally advanced, inflammatory, or early breast
cancer</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span>APHINITY,
in which adjuvant Perjeta was given in combination with trastuzumab and
anthracycline-based or non-anthracycline-based, taxane-containing chemotherapy
to patients with early breast cancer (n=2364)</p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>In addition,
ADRs reported in the post-marketing setting are included in Table 2. As Perjeta
was used with trastuzumab and </span><span lang=EN-GB>chemotherapy in these
trials</span><span lang=EN-GB>, it is difficult to ascertain the causal
relationship of an adverse event to a particular medicinal product. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The ADRs are
listed below by MedDRA system organ class (SOC) and categories of frequency: </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Very common
(&#8805;&nbsp;1/10)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Common
(&#8805;&nbsp;1/100 to &lt;&nbsp;1/10)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Uncommon(
&#8805;&nbsp;1/1,000 to &lt;&nbsp;1/100)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Rare (</span><span
lang=EN-GB>&#8805;&nbsp;</span><span lang=EN-GB>1/10,000 to &lt;&nbsp;1/1,000)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Very rare
(&lt;&nbsp;1/10,000)</span></p>

<p class=MsoNormal><span lang=EN-GB>Not known (cannot be estimated from the
available data)</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Within each frequency grouping and SOC, ADRs
are presented in the order of decreasing seriousness.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The most common ADRs (&#8805;30%) from this
pooled data were diarrhoea, alopecia, nausea, fatigue, neutropenia, and
vomiting. The most common NCI-CTCAE Grade 3-4 ADRs (&#8805;10%) were
neutropenia and febrile neutropenia.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in;page-break-after:
avoid'><b><span lang=EN-GB>Table 2 Summary of ADRs </span></b><b><span
lang=EN-GB>in patients treated with Perjeta in clinical trials^, and in the Post-marketing
setting</span></b><span lang=EN-GB style='font-size:10.0pt'></span><b><span
lang=EN-GB> </span></b><b><span lang=EN-GB style='color:black'></span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=723
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='height:31.65pt'>
   <td width=161 nowrap style='width:120.45pt;border:solid windowtext 1.5pt;
   padding:0in 4.25pt 0in 4.25pt;height:31.65pt'>
   <p class=MsoNormal style='margin-left:-.05pt;text-indent:.05pt;page-break-after:
   avoid;text-autospace:none'><b><span lang=EN-GB style='color:black'>System </span></b><b><span
   lang=EN-GB style='color:black'>organ class</span></b></p>
   </td>
   <td width=141 nowrap style='width:105.45pt;border:solid windowtext 1.5pt;
   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:31.65pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid;text-autospace:none'><b><i><u><span lang=EN-GB style='font-size:10.0pt;
   color:black'>Very Common</span></u></i></b></p>
   </td>
   <td width=141 nowrap style='width:105.5pt;border:solid windowtext 1.5pt;
   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:31.65pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid;text-autospace:none'><b><i><u><span lang=EN-GB style='font-size:10.0pt;
   color:black'>Common</span></u></i></b></p>
   </td>
   <td width=141 nowrap style='width:105.45pt;border:solid windowtext 1.5pt;
   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:31.65pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid;text-autospace:none'><b><i><u><span lang=EN-GB style='font-size:10.0pt;
   color:black'>Uncommon</span></u></i></b></p>
   </td>
   <td width=141 style='width:105.5pt;border:solid windowtext 1.5pt;border-left:
   none;padding:0in 4.25pt 0in 4.25pt;height:31.65pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid;text-autospace:none'><b><i><u><span lang=EN-GB style='font-size:10.0pt;
   color:black'>Rare</span></u></i></b></p>
   </td>
  </tr>
 </thead>
 <tr style='height:29.6pt'>
  <td width=161 nowrap valign=top style='width:120.45pt;border:solid windowtext 1.5pt;
  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:29.6pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Infections and infestations</span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:29.6pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Nasopharyngitis</span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:29.6pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Paronychia</span><span
  lang=EN-GB style='font-size:10.0pt;color:black'> </span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Upper respiratory tract
  infection</span><span lang=EN-GB style='font-size:10.0pt;color:black'> </span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:29.6pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=141 valign=top style='width:105.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:29.6pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:27.05pt'>
  <td width=161 nowrap valign=top style='width:120.45pt;border:solid windowtext 1.5pt;
  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:27.05pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Blood and lymphatic system</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>disorders</span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:27.05pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=IT style='font-size:10.0pt;color:black'>Febrile neutropenia*</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=IT style='font-size:10.0pt;color:black'>Neutropenia</span><span lang=IT
  style='font-size:10.0pt;color:black'> </span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=IT style='font-size:10.0pt;color:black'>Leucopenia </span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=IT style='font-size:10.0pt;color:black'>Anaemia</span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:27.05pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=IT style='font-size:10.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:27.05pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=IT style='font-size:10.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=141 valign=top style='width:105.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:27.05pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=IT style='font-size:10.0pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:27.05pt'>
  <td width=161 nowrap valign=top style='width:120.45pt;border:solid windowtext 1.5pt;
  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:27.05pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Immune system disorders</span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:27.05pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Infusion reaction, *</span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:27.05pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Hypersensitivity</span><span
  lang=EN-GB style='font-size:10.0pt;color:black'>, *</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Drug hypersensitivity, *</span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:27.05pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Anaphylactic reaction, *</span></p>
  </td>
  <td width=141 valign=top style='width:105.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:27.05pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Cytokine release syndrome</span></p>
  </td>
 </tr>
 <tr style='height:27.05pt'>
  <td width=161 nowrap valign=top style='width:120.45pt;border:solid windowtext 1.5pt;
  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:27.05pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Metabolism and nutrition
  disorders</span><span lang=EN-GB style='font-size:10.0pt;color:black'> </span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:27.05pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Decreased appetite</span><span
  lang=EN-GB style='font-size:10.0pt;color:black'> </span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:27.05pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:27.05pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=141 valign=top style='width:105.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:27.05pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Tumour lysis syndrome</span></p>
  </td>
 </tr>
 <tr style='height:15.55pt'>
  <td width=161 nowrap valign=top style='width:120.45pt;border:solid windowtext 1.5pt;
  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:15.55pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Psychiatric disorders</span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:15.55pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Insomnia</span><span
  lang=EN-GB style='font-size:10.0pt;color:black'> </span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:15.55pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:15.55pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=141 valign=top style='width:105.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:15.55pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=161 nowrap valign=top style='width:120.45pt;border:solid windowtext 1.5pt;
  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:13.05pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Nervous system disorders</span><span
  lang=EN-GB style='font-size:10.0pt;color:black'> </span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:13.05pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Neuropathy peripheral</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Headache </span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Dysgeusia</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Peripheral sensory neuropathy</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Dizziness</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Paraesthesia</span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:13.05pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:13.05pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'></span></p>
  </td>
  <td width=141 valign=top style='width:105.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:13.05pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:18.2pt'>
  <td width=161 nowrap valign=top style='width:120.45pt;border:solid windowtext 1.5pt;
  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Eye disorders</span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:18.2pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Lacrimation increased</span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:18.2pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:18.2pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=141 valign=top style='width:105.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:18.2pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:18.2pt'>
  <td width=161 nowrap valign=top style='width:120.45pt;border:solid windowtext 1.5pt;
  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Cardiac disorders</span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:18.2pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:18.2pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Left ventricular dysfunction</span><span
  lang=EN-GB style='font-size:10.0pt;color:black'> </span><span lang=EN-GB
  style='font-size:10.0pt;color:black'>**</span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:18.2pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Cardiac failure congestive</span><span
  lang=EN-GB style='font-size:10.0pt;color:black'>**</span></p>
  </td>
  <td width=141 valign=top style='width:105.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:18.2pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:18.2pt'>
  <td width=161 nowrap valign=top style='width:120.45pt;border:solid windowtext 1.5pt;
  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt;color:black'>Vascular disorders</span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:18.2pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt;color:black'>Hot flush</span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:18.2pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:18.2pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=141 valign=top style='width:105.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:18.2pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:18.2pt'>
  <td width=161 nowrap valign=top style='width:120.45pt;border:solid windowtext 1.5pt;
  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt;color:black'>Respiratory, thoracic and mediastinal
  disorders</span><span lang=EN-GB style='font-size:10.0pt;color:black'> </span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:18.2pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt;color:black'>Cough </span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>Epistaxis</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>Dyspnoea</span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:18.2pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:18.2pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt;color:black'>Interstitial lung disease </span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt;color:black'>Pleural effusion</span><span lang=EN-GB
  style='font-size:10.0pt;color:black'> </span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=141 valign=top style='width:105.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:18.2pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:11.6pt'>
  <td width=161 nowrap valign=top style='width:120.45pt;border:solid windowtext 1.5pt;
  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:11.6pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt;color:black'>Gastrointestinal disorders</span><span
  lang=EN-GB style='font-size:10.0pt;color:black'> </span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:11.6pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt;color:black'>Diarrhoea</span><span lang=EN-GB
  style='font-size:10.0pt;color:black'> </span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt;color:black'>Vomiting </span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt;color:black'>Stomatitis</span><span lang=EN-GB
  style='font-size:10.0pt;color:black'> </span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt;color:black'>Nausea </span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt;color:black'>Constipation </span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt;color:black'>Dyspepsia </span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt;color:black'>Abdominal pain</span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:11.6pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
  style='font-size:10.0pt;color:black'>&nbsp;</span></b></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:11.6pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
  style='font-size:10.0pt;color:black'>&nbsp;</span></b></p>
  </td>
  <td width=141 valign=top style='width:105.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:11.6pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
  style='font-size:10.0pt;color:black'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:37.4pt'>
  <td width=161 nowrap valign=top style='width:120.45pt;border:solid windowtext 1.5pt;
  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:37.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Skin and subcutaneous tissue
  disorders</span><span lang=EN-GB style='font-size:10.0pt;color:black'> </span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:37.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Alopecia</span><span
  lang=EN-GB style='font-size:10.0pt;color:black'> </span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Rash </span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Nail disorder</span><span
  lang=EN-GB style='font-size:10.0pt;color:black'> </span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Pruritus</span><span
  lang=EN-GB style='font-size:10.0pt;color:black'> </span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Dry skin</span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:37.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:37.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=141 valign=top style='width:105.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:37.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:26.45pt'>
  <td width=161 nowrap valign=top style='width:120.45pt;border:solid windowtext 1.5pt;
  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:26.45pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt;color:black'>Musculoskeletal and connective tissue disorders</span><span
  lang=EN-GB style='font-size:10.0pt;color:black'> </span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:26.45pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt;color:black'>Myalgia</span><span lang=EN-GB
  style='font-size:10.0pt;color:black'> </span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt;color:black'>Arthralgia</span><span lang=EN-GB
  style='font-size:10.0pt;color:black'> </span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt;color:black'>Pain in extremity</span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:26.45pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:26.45pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=141 valign=top style='width:105.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:26.45pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:12.55pt'>
  <td width=161 nowrap valign=top style='width:120.45pt;border:solid windowtext 1.5pt;
  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:12.55pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>General disorders and
  administration site conditions </span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:12.55pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Mucosal inflammation</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=PT-BR style='font-size:10.0pt;color:black'>Oedema peripheral</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=PT-BR style='font-size:10.0pt;color:black'>Pyrexia</span><span
  lang=PT-BR style='font-size:10.0pt;color:black'> </span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=PT-BR style='font-size:10.0pt;color:black'>Fatigue</span><span
  lang=PT-BR style='font-size:10.0pt;color:black'> </span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=PT-BR style='font-size:10.0pt;color:black'>Asthenia </span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:12.55pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Chills</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Pain</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Oedema</span></p>
  </td>
  <td width=141 nowrap valign=top style='width:105.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:12.55pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=141 valign=top style='width:105.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 4.25pt 0in 4.25pt;height:12.55pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><sup><span
lang=EN-GB style='font-size:10.0pt'>^ </span></sup></b><span lang=EN-GB
style='font-size:10.0pt'>Table 2 shows pooled data from the overall treatment
period in CLEOPATRA (data cutoff 11 February 2014; median number of cycles of
Perjeta was 24); and from the neoadjuvant treatment period in NEOSPHERE
(median number of cycles of Perjeta was 4, across all treatment arms) and
TRYPHAENA (median number of cycles of Perjeta was 3  6 across treatment arms) </span><span
style='font-size:10.0pt'>and from the treatment period of APHINITY (median
number of cycles of Perjeta was 18). <sup></sup></span><span style='font-size:
10.0pt'><sup></sup></span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB style='font-size:10.0pt'>* ADRs with a fatal outcome have been
reported</span><span lang=EN-GB style='font-size:10.0pt'>. </span></p>

<p class=MsoNormal style='margin-left:9.0pt;text-indent:-9.0pt;page-break-after:
avoid;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>** For the
overall treatment period across the 4 studies. The incidence of left
ventricular dysfunction and cardiac failure congestive reflect the MedDRA
Preferred Terms reported in the individual studies.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:10.0pt'> </span><span lang=EN-GB style='font-size:10.0pt'>Hypersensitivity/anaphylactic
reaction is based on a group of terms.</span></p>

<p class=MsoNormal style='margin-left:9.0pt;text-indent:-9.0pt;page-break-after:
avoid'><span lang=EN-GB style='font-size:10.0pt'> Infusion reaction includes
a range of different terms within a time window, see Description of selected
adverse reactions below. </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:10.0pt'> ADRs reported in the post marketing setting</span><u><span
lang=EN-GB>-</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Description
of selected adverse reactions</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'><i><span
lang=EN-GB>Left ventricular dysfunction (LVD)</span></i></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'><span
lang=EN-GB>In the pivotal trial CLEOPATRA in metastatic breast cancer, the
incidence of LVD during study treatment was higher in the placebo-treated group
than in the Perjeta-treated group (8.6% and 6.6%, respectively). The incidence
of symptomatic LVD was also lower in the Perjeta-treated group (1.8% in the
placebo-treated group vs. 1.5% in the Perjeta-treated group) (see section 4.4).
</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'><span
lang=EN-GB>In the neoadjuvant trial NEOSPHERE, in which patients received 4
cycles of Perjeta as neoadjuvant treatment, the incidence of LVD (during the
overall treatment period) was higher in the Perjeta, trastuzumab and
docetaxel-treated group (7.5%) compared to the trastuzumab and
docetaxel-treated group (1.9%). There was one case of symptomatic LVD in the
Perjeta and trastuzumab-treated group. </span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'><span
lang=EN-GB>In the neoadjuvant trial TRYPHAENA, the incidence of LVD (during the
overall treatment period) was 8.3% in the group treated with Perjeta plus
trastuzumab and FEC </span>(5-fluorouracil, epirubicin, cyclophosphamide)<span
lang=EN-GB> followed by Perjeta plus trastuzumab and docetaxel; 9.3% in the
group treated with Perjeta plus trastuzumab and docetaxel following FEC; and
6.6% in the group treated with Perjeta in combination with TCH </span>(docetaxel,
carboplatin and trastuzumab)<span lang=EN-GB>. The incidence of symptomatic LVD
(congestive heart failure) was 1.3% in the group treated with Perjeta plus
trastuzumab and docetaxel following FEC (this excludes a patient who
experienced symptomatic LVD during FEC treatment prior to receiving Perjeta
plus trastuzumab and docetaxel) and also 1.3% in the group treated with Perjeta
in combination with TCH. No patients in the group treated with Perjeta plus
trastuzumab and FEC followed by Perjeta plus trastuzumab and docetaxel
experienced symptomatic LVD.</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the neoadjuvant period of the BERENICE
trial, the incidence of NYHA Class III/IV symptomatic LVD (congestive heart
failure</span><span lang=EN-CARRIBEAN> according to </span>NCI-CTCAE v.4<span
lang=EN-GB>) was 1.5% in the group treated with dose dense doxorubicin and
cyclophosphamide (AC) followed by Perjeta plus trastuzumab and paclitaxel and none
of the patients (0%) experienced symptomatic LVD in the group treated with FEC
followed by Perjeta in combination with trastuzumab and docetaxel. The
incidence of asymptomatic LVD (ejection fraction decrease </span><span
lang=EN-CARRIBEAN>according to </span>NCI-CTCAE v.4)<span lang=EN-GB> was 7% in
the group treated with dose dense AC followed by Perjeta plus trastuzumab and
paclitaxel and 3.5% in the group treated with FEC followed by Perjeta plus
trastuzumab and docetaxel.</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'>&nbsp;</p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'>In
APHINITY, the incidence of symptomatic heart failure (NYHA class III or IV)
with a LVEF decline of at least 10% points from baseline and to &lt;50% was
&lt;1% (0.6% of Perjeta-treated patients vs 0.3% of placebo-treated patients).
Of the patients who experienced symptomatic heart failure, 46.7% of
Perjeta-treated patients and 57.1% of placebo-treated patients had recovered
(defined as 2 consecutive LVEF measurements above 50%) at the data cutoff. The
majority of the events were reported in anthracycline-treated patients. Asymptomatic
or mildly symptomatic (NYHA class II) declines in LVEF of at least 10% points
from baseline and to &lt;50% were reported in 2.7% of Perjeta-treated patients
and 2.8% of placebo-treated patients, of whom 79.7% of Perjeta-treated patients
and 80.6% of placebo-treated patients had recovered at the data cutoff. </p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>Infusion reactions</span></i></p>

<p class=MsoNormal><span lang=EN-GB>An infusion reaction was defined in the
pivotal trials as any event reported as hypersensitivity, anaphylactic
reaction, acute infusion reaction or cytokine release syndrome occurring during
an infusion or on the same day as the infusion. In the pivotal trial CLEOPATRA,
the initial dose of Perjeta was given the day before trastuzumab and docetaxel
to allow for the examination of Perjeta-associated reactions. On the first day
when only Perjeta was administered, the overall frequency of infusion reactions
was 9.8% in the placebo-treated group and 13.2% in the Perjeta-treated group,
with the majority of infusion reactions being mild or moderate. The most common
infusion reactions (</span><span lang=EN-GB>&#8805;</span><span lang=EN-GB>&nbsp;1.0%)
in the Perjeta-treated group were pyrexia, chills, fatigue, headache, asthenia,
hypersensitivity and vomiting.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>During the second cycle when all medicinal
products were administered on the same day, the most common infusion reactions
in the Perjeta-treated group (</span><span lang=EN-GB>&#8805;</span><span
lang=EN-GB>&nbsp;1.0%) were fatigue, dysgeusia, </span><span lang=EN-GB>drug </span><span
lang=EN-GB>hypersensitivity, myalgia and vomiting (see section 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In neoadjuvant and adjuvant trials, Perjeta
was administered on the same day as other study treatments in all cycles.
Infusion reactions occurred in 18.6% - 25.0% of patients on the first day of
Perjeta administration (in combination with trastuzumab and chemotherapy). The
type and severity of events were consistent with those observed in CLEOPATRA at
the cycles when Perjeta was given on the same day as trastuzumab and docetaxel,
with the majority of reactions being mild or moderate in severity.</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>Hypersensitivity reactions/anaphylaxis</span></i></p>

<p class=MsoNormal><span lang=EN-GB>In the pivotal trial CLEOPATRA</span><span
lang=EN-GB> in metastatic breast cancer</span><span lang=EN-GB>, the overall
frequency of investigator reported hypersensitivity/anaphylaxis events during
the entire treatment period was 9.3% in the placebo-treated group and 11.3% in
the Perjeta-treated group, of which 2.5% and 2.0% were <br>
NCI-CTCAE Grade 3-4, respectively. Overall, 2 patients in the placebo-treated
group and 4 patients in the Perjeta-treated group experienced </span><span
lang=EN-GB>events described as </span><span lang=EN-GB>anaphylaxis </span><span
lang=EN-GB>by the investigator </span><span lang=EN-GB>(see section 4.4). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Overall, the majority of hypersensitivity
reactions were mild or moderate in severity and resolved upon treatment. Based
on modifications made to the study treatment, most reactions were assessed as
secondary to docetaxel infusions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the neoadjuvant and adjuvant trials,
hypersensitivity/anaphylaxis events were consistent with those observed in
CLEOPATRA. In NEOSPHERE, two patients in the Perjeta and docetaxel-treated
group experienced anaphylaxis. In both the TRYPHAENA and APHINITY trials, the
overall frequency of hypersensitivity/anaphylaxis was highest in the Perjeta
and TCH treated group (13.2% and 7.6%, respectively), of which 2.6% and 1.3% of
events, respectively, were NCI-CTCAE Grade 3-4.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Febrile
neutropenia</span></i></p>

<p class=MsoNormal><span lang=EN-GB>In the pivotal trial CLEOPATRA, the
majority of patients in both treatment groups experienced at least one
leucopenic event (63.0% of patients in the Perjeta-treated group and 58.3% of
patients in the placebo-treated group), of which the majority were neutropenic
events (see section 4.4). Febrile neutropenia occurred in 13.7% of Perjeta-treated
patients and 7.6% of placebo-treated patients. In both treatment groups, the
proportion of patients experiencing febrile neutropenia was highest in the
first cycle of therapy and declined steadily thereafter. An increased incidence
of febrile neutropenia was observed </span><span lang=EN-GB>among</span><span
lang=EN-GB> Asian patients in both treatment groups compared with patients of
other races and from other geographic regions. Among Asian patients, the
incidence of febrile neutropenia was higher in the Perjeta-treated group (25.8%)
compared with the placebo-treated group (11.3%).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the NEOSPHERE trial, 8.4% of patients
treated with neoadjuvant Perjeta, trastuzumab and docetaxel experienced febrile
neutropenia compared with 7.5% of patients treated with trastuzumab and
docetaxel. In the TRYPHAENA trial, febrile neutropenia occurred in 17.1% of
patients treated with neoadjuvant Perjeta + TCH, and 9.3% of patients treated
with neoadjuvant Perjeta, trastuzumab and docetaxel following FEC. In TRYPHAENA,
the incidence of febrile neutropenia was higher in patients who received six
cycles of Perjeta compared with patients who received three cycles of Perjeta,
independent of the chemotherapy given. As in the CLEOPATRA trial, a higher
incidence of neutropenia and febrile neutropenia was observed among Asian
patients compared with other patients in both neoadjuvant trials. In NEOSPHERE,
8.3% of Asian patients treated with neoadjuvant Perjeta, trastuzumab and
docetaxel experienced febrile neutropenia compared with 4.0% of Asian patients
treated with neoadjuvant trastuzumab and docetaxel.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the APHINITY trial, febrile neutropenia
occurred in 12.1% of Perjeta-treated patients and 11.1% of placebo-treated
patients. As in the CLEOPATRA, TRYPHAENA, and NEOSPHERE trials, a higher
incidence of febrile neutropenia was observed among Perjeta-treated Asian
patients compared with other races in the APHINITY trial (15.9% of
Perjeta-treated patients and 9.9% of placebo-treated patients).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Diarrhoea</span></i></p>

<p class=MsoNormal><span lang=EN-GB>In the pivotal trial CLEOPATRA</span><span
lang=EN-GB> in metastatic breast cancer</span><span lang=EN-GB>, diarrhoea
occurred in 68.4% of Perjeta-treated patients and 48.7% of placebo-treated
patients (see section 4.4). Most events were mild</span><span lang=EN-GB> to </span><span
lang=EN-GB>moderate in severity and occurred in the first few cycles of
treatment. The incidence of NCI-CTCAE Grade 3-4 diarrhoea was 9.3% in Perjeta-treated
patients vs 5.1% in placebo-treated patients. The median duration of the longest
episode was 18 days in Perjeta-treated patients and 8 days in placebo-treated
patients. Diarrhoeal events responded well to proactive management with
anti-diarrhoeal agents.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the NEOSPHERE trial, diarrhoea occurred
in 45.8% of patients treated with neoadjuvant Perjeta, trastuzumab and
docetaxel compared with 33.6% of patients treated with trastuzumab and
docetaxel. In the TRYPHAENA trial, diarrhoea occurred in 72.3% of patients
treated with neoadjuvant Perjeta+TCH and 61.4% of patients treated with
neoadjuvant Perjeta, trastuzumab and docetaxel following FEC. In both studies
most events were mild to moderate in severity. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the APHINITY trial, a higher incidence
of diarrhoea was reported in the Perjeta-treated arm (71.2%) compared to the
placebo arm (45.2%). Grade &#8805; 3 diarrhoea was reported in 9.8% of
patients in the Perjeta arm vs. 3.7% in the placebo arm. The majority of the
reported events were Grade 1 or 2 in severity. The highest incidence of
diarrhoea (all Grades) was reported during the targeted therapy+taxane
chemotherapy period (61.4% of patients in the Perjeta arm vs. 33.8% of patients
in the placebo arm).The incidence of diarrhoea was much lower after
chemotherapy cessation, affecting 18.1% of patients in the Perjeta arm vs. 9.2%
of patients in the placebo arm in the post-chemotherapy targeted therapy
period.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Rash</span></i></p>

<p class=MsoNormal><span lang=EN-GB>In the pivotal trial CLEOPATRA in
metastatic breast cancer, r</span><span lang=EN-GB>ash occurred in 51.7% of Perjeta-treated
patients, compared with 38.9% of placebo-treated patients. Most events were
Grade 1 or 2 in severity, occurred in the first two cycles, and responded to
standard therapies, such as topical or oral treatment for acne.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the NEOSPHERE trial, rash occurred in
40.2% of patients treated with neoadjuvant Perjeta, trastuzumab and docetaxel
compared with 29.0% of patients treated with trastuzumab and docetaxel. In the
TRYPHAENA trial, rash occurred in 36.8% of patients treated with neoadjuvant
Perjeta + TCH and 20.0% of patients treated with neoadjuvant Perjeta,
trastuzumab and docetaxel following FEC. The incidence of rash was higher in
patients who received six cycles of Perjeta compared with patients who received
three cycles of Perjeta, independent of the chemotherapy given.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the APHINITY trial, the adverse event of
rash occurred in 25.8% of patients in Perjeta arm vs. 20.3% of patients in
placebo arm. The majority of rash events were Grade 1 or 2.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Laboratory abnormalities</span></i></p>

<p class=MsoNormal><span lang=EN-GB>In the pivotal trial CLEOPATRA in
metastatic breast cancer, the</span><span lang=EN-GB> incidence of NCI-CTCAE </span><span
lang=EN-GB>v.</span><span lang=EN-GB>3 Grade 3-4 neutropenia was balanced in
the two treatment groups (86.3% of Perjeta-treated patients and 86.6% of
placebo-treated patients, including 60.7% and 64.8% Grade 4 neutropenia,
respectively).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the NEOSPHERE trial, the incidence of
NCI-CTCAE v.3 Grade 3-4 neutropenia was 74.5% in patients treated with
neoadjuvant Perjeta, trastuzumab and docetaxel compared with 84.5% in patients
treated with trastuzumab and docetaxel, including 50.9% and 60.2% Grade 4
neutropenia, respectively. In the TRYPHAENA trial, the incidence of NCI-CTCAE
v.3 Grade 3-4 neutropenia was 85.3% in patients treated with neoadjuvant Perjeta
+ TCH and 77.0% in patients treated with neoadjuvant Perjeta, trastuzumab and
docetaxel following FEC, including 66.7% and 59.5% Grade 4 neutropenia,
respectively. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the APHINITY trial, the incidence of
NCI-CTCAE v.4 Grade 3-4 neutropenia was 40.6% in patients treated with Perjeta,
trastuzumab and chemotherapy compared with 39.1% in patients treated with
placebo, trastuzumab and chemotherapy, including 28.3% and 26.5% Grade 4
neutropenia, respectively.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Elderly Patients</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>The incidence of the following all grade adverse events was
at least 5% higher in patients &#8805;&nbsp;65&nbsp;years of age, compared to
patients &lt;&nbsp;65&nbsp;years of age: decreased appetite, anaemia, weight
decreased, asthenia, dysgeusia, peripheral neuropathy, hypomagnesemia and
diarrhoea. Limited data are available in patients &gt; 75 years of age. </p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:13.0pt;text-autospace:none'><span
lang=EN-GB>Reporting suspected adverse reactions after authorisation of the
medicinal product is important. It allows continued monitoring of the
benefit/risk balance of the medicinal product. Healthcare professionals are
asked to report any suspected adverse reactions via </span><span lang=EN-GB
style='background:lightgrey'>the national reporting system listed in </span><a
href="https://www.ema.europa.eu/documents/template-form/appendix-v-adverse-drug-reaction-reporting-details_en.doc"><span
lang=EN-GB style='background:lightgrey'>Appendix V.</span></a></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>4.9 Overdose</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The maximum tolerated dose of </span><span
lang=EN-GB>pertuzumab has not been determined. In clinical trials, single doses
higher than 25&nbsp;mg/kg (1727&nbsp;mg) have not been tested.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In case of overdose, patients must be
closely monitored for signs or symptoms of adverse reactions and appropriate
symptomatic treatment instituted.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>5. PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>5.1 Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Pharmacotherapeutic
group: Antineoplastic agents, monoclonal antibodies, ATC code: L01XC13</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Mechanism
of action</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Pertuzumab</span><span lang=EN-GB> is a
recombinant humanised monoclonal antibody that specifically targets the
extracellular dimerization domain (subdomain II) of the human epidermal growth
factor receptor 2 protein (HER2), and thereby, blocks ligand-dependent
heterodimerisation of HER2 with other HER family members, including EGFR, HER3
and HER4. As a result, pertuzumab inhibits ligand&#8209;initiated intracellular
signalling through two major signal pathways, mitogen&#8209;activated protein
(MAP) kinase and phosphoinositide&nbsp;3&#8209;kinase (PI3K). Inhibition of
these signalling pathways can result in cell growth arrest and apoptosis,
respectively. In addition, pertuzumab mediates antibody-dependent cell-mediated
cytotoxicity (ADCC).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>While pertuzumab alone inhibited the
proliferation of human tumour cells, the combination of pertuzumab and
trastuzumab significantly augmented antitumour activity in HER2-overexpressing
xenograft models.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Clinical
efficacy and safety</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>The efficacy of Perjeta in HER2-positive
breast cancer is supported by a randomised phase III trial and a single-arm
phase II trial in metastatic breast cancer, two randomised neoadjuvant phase II
trials in early breast cancer (one controlled), a non-randomised neoadjuvant
phase II trial, and a randomised phase III trial in the adjuvant setting.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>HER2 overexpression was determined at a
central laboratory and defined as a score of 3+ by IHC or an ISH amplification
ratio &#8805;2.0 in the trials outlined below.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Metastatic
</span></u></i><i><u><span lang=EN-GB>breast cancer </span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Perjeta in combination with trastuzumab
and docetaxel</span></i></p>

<p class=MsoNormal><span lang=EN-GB>CLEOPATRA</span><span lang=EN-GB> (WO20698)</span><span
lang=EN-GB> is a multicentre, randomised, double-blind, placebo-controlled
phase III clinical trial conducted in 808 patients with HER2-positive
metastatic or locally recurrent unresectable breast cancer. Patients with clinically
important cardiac risk factors were not included (see section 4.4). Due to the
exclusion of patients with brain metastases no data are available on Perjeta
activity on brain metastases. There is very limited data available in patients
with unresectable locally recurrent disease. Patients were randomised 1:1 to
receive placebo + trastuzumab + docetaxel or Perjeta + trastuzumab + docetaxel.
</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Perjeta and trastuzumab were given at
standard doses in a 3-weekly regimen. Patients were treated with Perjeta and trastuzumab
until disease progression, withdrawal of consent or unmanageable toxicity.
Docetaxel was given as an initial dose of 75&nbsp;mg/m<sup>2</sup> as an
intravenous infusion every three weeks for at least 6 cycles. The dose of
docetaxel could be escalated to 100&nbsp;mg/m<sup>2</sup> at the investigators
discretion if the initial dose was well tolerated. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The primary endpoint of the study was
progression-free survival (PFS) as assessed by an independent review facility
(IRF) and defined as the time from the date of randomisation to the date of
disease progression or death (from any cause) if the death occurred within 18
weeks of the last tumour assessment. </span><span lang=EN-GB>Secondary efficacy
endpoints were overall survival (OS), PFS (investigator-assessed), objective
response rate (ORR), duration of response, and time to symptom progression
according to the FACT B Quality of Life questionnaire.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Approximately half the patients in each
treatment group had hormone receptor-positive disease (defined as o</span><span
lang=EN-GB>estrogen</span><span lang=EN-GB> receptor</span><span lang=EN-GB>
(ER) </span><span lang=EN-GB>positive and/or progesterone receptor</span><span
lang=EN-GB> (PgR) </span><span lang=EN-GB>positive) and approximately half of
the patients in each treatment group had received prior adjuvant or neoadjuvant
therapy. Most of these patients had received prior anthracycline therapy and 11%
of all patients had received prior trastuzumab. A total of 43% of patients in
both treatment groups had previously received radiotherapy. Patients median LVEF
at baseline was 65.0% (range 50%  88%) in both groups. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The efficacy results from the CLEOPATRA
study are summarised in Table 3. </span><span lang=EN-GB>A statistically
significant improvement in IRF-assessed PFS was demonstrated in the Perjeta-treated
group compared with the placebo-treated group. The results for investigator-assessed
PFS were similar to those observed for IRF-assessed PFS. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Table 3  Summary
of efficacy from CLEOPATRA study</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width=217 valign=top style='width:163.05pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
   page-break-after:avoid;text-autospace:none'><b><span lang=EN-GB>Parameter </span></b></p>
   </td>
   <td width=94 valign=top style='width:70.85pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid;text-autospace:none'><b><span lang=EN-GB>Placebo+ </span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid;text-autospace:none'><b><span lang=EN-GB>trastuzumab</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid;text-autospace:none'><b><span lang=EN-GB>+ docetaxel</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid;text-autospace:none'><b><span lang=EN-GB>n=406</span></b></p>
   </td>
   <td width=95 valign=top style='width:70.9pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid;text-autospace:none'><b><span lang=EN-GB>Perjeta+ </span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid;text-autospace:none'><b><span lang=EN-GB>trastuzumab</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid;text-autospace:none'><b><span lang=EN-GB>+ docetaxel</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid;text-autospace:none'><b><span lang=EN-GB>n=402</span></b></p>
   </td>
   <td width=85 valign=top style='width:63.75pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid;text-autospace:none'><b><span lang=EN-GB>HR</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid;text-autospace:none'><b><span lang=EN-GB>(95% CI)</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid;text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>
   </td>
   <td width=95 valign=top style='width:70.9pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid;text-autospace:none'><b><span lang=EN-GB>p-value</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width=217 valign=top style='width:163.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
  page-break-after:avoid;text-autospace:none'><b><span lang=EN-GB>Progression-Free
  Survival </span></b></p>
  <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
  page-break-after:avoid;text-autospace:none'><b><span lang=EN-GB>(independent
  review)  primary endpoint*</span></b></p>
  <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
  page-break-after:avoid;text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB>no. of patients
  with an event</span></p>
  <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB>Median months</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>242 (59%)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>12.4</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>191 (47.5%)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>18.5</span></p>
  </td>
  <td width=85 valign=top style='width:63.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>0.62</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>[0.51;0.75]</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=217 valign=top style='width:163.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=EN-GB>Overall Survival - secondary endpoint**</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>no. of patients with an event</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Median months</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><s><span lang=EN-GB><span style='text-decoration:
   none'>&nbsp;</span></span></s></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><s><span lang=EN-GB><span style='text-decoration:
   none'>&nbsp;</span></span></s></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><s><span lang=EN-GB><span style='text-decoration:
   none'>&nbsp;</span></span></s></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>221 (54.4%)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>40.8</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><s><span lang=EN-GB><span style='text-decoration:
   none'>&nbsp;</span></span></s></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><s><span lang=EN-GB><span style='text-decoration:
   none'>&nbsp;</span></span></s></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><s><span lang=EN-GB><span style='text-decoration:
   none'>&nbsp;</span></span></s></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>168 (41.8%)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>56.5</span></p>
  </td>
  <td width=85 valign=top style='width:63.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><s><span lang=EN-GB><span style='text-decoration:
   none'>&nbsp;</span></span></s></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>0.68</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>[0.56;0.84]</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><s><span lang=EN-GB><span style='text-decoration:
   none'>&nbsp;</span></span></s></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><s><span lang=EN-GB><span style='text-decoration:
   none'>&nbsp;</span></span></s></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><s><span lang=EN-GB><span style='text-decoration:
   none'>&nbsp;</span></span></s></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>0.0002</span></p>
  </td>
 </tr>
 <tr style='height:21.0pt'>
  <td width=217 valign=top style='width:163.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:21.0pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=EN-GB>Objective Response Rate (ORR)^ - secondary endpoint</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>no. of patients with measurable disease</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Responders***
  </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>95% CI for
  ORR </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Complete
  response (CR) </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Partial
  Response (PR) </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Stable
  disease (SD) </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Progressive
  disease (PD) </span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:21.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>336</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>233 (69.3%)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>[64.1; 74.2]</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>14 (4.2%)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>219 (65.2%)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>70 (20.8%)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>28 (8.3%)</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:21.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>343</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>275 (80.2%)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>[75.6; 84.3]</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>19 (5.5%)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>256 (74.6%)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>50 (14.6%)</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>13 (3.8 %)</span></p>
  </td>
  <td width=85 valign=top style='width:63.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:21.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>Difference in ORR:</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>10.8%</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>[4.2,17.5]</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:21.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>0.0011</span></p>
  </td>
 </tr>
 <tr>
  <td width=217 valign=top style='width:163.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Duration
  of Response </span></b><span lang=EN-GB><b>^</b></span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>n=</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Median weeks </span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>95% CI for
  Median</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=EN-GB>233</span></p>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=EN-GB>54.1</span></p>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=EN-GB>[46;64]</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=EN-GB>275</span></p>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=EN-GB>87.6</span></p>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=EN-GB>[71;106]</span></p>
  </td>
  <td width=85 valign=top style='width:63.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:9.0pt;text-indent:-9.0pt'><span
lang=EN-GB style='font-size:10.0pt'>* Primary progression-free survival
analysis, cutoff date 13<sup>th</sup> May 2011.</span></p>

<p class=MsoNormal style='margin-left:9.0pt;text-indent:-9.0pt'><span
lang=EN-GB style='font-size:10.0pt'>**</span><span lang=EN-GB style='font-size:
10.0pt'> Event-driven final overall survival analysis, cutoff date 11<sup>th</sup>
February 2014.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>*** Patients with
best overall response of confirmed CR or PR by RECIST.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Evaluated in
patients with Best Overall Response of CR or PR</span><span lang=EN-GB
style='font-size:10.0pt'>.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>^ Objective
response rate and duration of response are based on IRF-assessed tumour
assessments</span><span lang=EN-GB style='font-size:10.0pt'>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Consistent results were observed across
pre-specified patient subgroups including the subgroups based on stratification
factors of geographic region and prior adjuvant/neoadjuvant therapy or de novo
metastatic breast cancer (see Figure 1). A post hoc exploratory analysis
revealed that for patients who had received prior trastuzumab (n = 88), the
hazard ratio for IRF-assessed PFS was 0.62 (95% CI 0.35, 1.07), compared with
0.60 (95% CI 0.43, 0.83) for patients who had received prior therapy which did
not include trastuzumab (n = 288).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in;page-break-after:
avoid'><b><span lang=EN-GB>Figure 1 IRF-assessed PFS by patient subgroup</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:6.0pt;line-height:12.0pt;page-break-after:
avoid'><img border=0 width=651 height=385 id="Picture 2"
src="Perjeta-II-48%20EN%20PI%20clean_files/image002.jpg" alt=picutre-01></p>

<p class=MsoNormal style='margin-bottom:6.0pt;line-height:12.0pt;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The event-driven final analysis of OS was
performed when 389 patients had died (221 in the placebo-treated group and 168
in the Perjeta-treated group). The statistically significant OS benefit in favour
of the Perjeta-treated group, </span><span style='color:#222222;background:
white'>previously observed at an interim analysis of OS (performed one year
after the primary analysis),&nbsp;</span><span lang=EN-GB>was maintained (HR
0.68, p = 0.0002 log-rank test). The median time to death was 40.8 months in
the placebo-treated group and 56.5 months in the Perjeta-treated group </span><span
lang=EN-GB>(see Table 3, Figure&nbsp;2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A descriptive analysis of OS performed at
the end of the study when 515 patients had died (280 in the placebo-treated
group and 235 in the Perjeta-treated group) showed that the statistically
significant OS benefit in favour of the Perjeta-treated group was maintained over
time after a median follow-up of 99 months (HR 0.69, p &lt; 0.0001 log-rank
test; median time to death 40.8 months [placebo-treated group] versus 57.1
months [Perjeta-treated group]). Landmark survival estimates at 8 years were
37% in the Perjeta-treated group and 23% in the placebo-treated group.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:62.95pt;text-indent:-62.95pt;page-break-after:
avoid'><b><span lang=EN-GB>Figure 2 Kaplan-Meier Curve of Event&#8209;Driven
Overall Survival</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:10.0pt;text-align:center;
line-height:115%;page-break-after:avoid'><img border=0 width=580 height=354
id="Picture 1" src="Perjeta-II-48%20EN%20PI%20clean_files/image003.jpg"></p>

<p class=MsoNormal align=center style='margin-bottom:10.0pt;text-align:center;
line-height:115%'><span lang=EN-GB style='font-size:8.0pt;line-height:115%'>HR=
hazard ratio; CI= confidence interval; Pla= placebo; Ptz= pertuzumab (Perjeta);
T= trastuzumab (Herceptin); D= docetaxel</span><span lang=EN-GB
style='font-size:8.0pt;line-height:115%'>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No statistically significant differences
were found between the two treatment groups in Health Related Quality of Life
as assessed by FACT-B TOI-PFB scores. </span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>Additional </span></i><i><span
lang=EN-GB>supportive clinical trial</span></i><i><span lang=EN-GB> information</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><b><span lang=EN-GB>BO17929</span></b><span lang=EN-GB> -<b>
</b>single-arm trial in metastatic breast cancer</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>BO17929 was a phase II, non-randomised study
in patients with metastatic breast cancer whose tumours had progressed during
treatment with trastuzumab. Treatment with Perjeta and trastuzumab resulted in
a response rate of 24.2%, with a further 25.8% of patients experiencing
stabilisation of disease lasting at least 6 months, indicating that Perjeta is
active </span><span lang=EN-GB>following</span><span lang=EN-GB> progression on
</span><span lang=EN-GB>trastuzumab.</span>&nbsp; </p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>Early Breast Cancer</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>Neoadjuvant
Treatment</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>In the neoadjuvant
setting, locally advanced and inflammatory breast cancers are considered as
high-risk irrespective of hormone receptor status. In early stage breast cancer,
tumor size, grade, hormone receptor status and lymph node metastases should be
taken into account in the risk assessment.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The indication in the
neoadjuvant treatment of breast cancer is based on demonstration of an
improvement in pathological complete response rate,</span><span lang=EN-GB> </span><span
lang=EN-GB style='color:black'>and trends to improvement in disease-free
survival that nevertheless do not establish or precisely measure a benefit with
regard to long-term outcomes, such as overall survival or disease-free
survival. </span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>NEOSPHERE (WO20697)</span></b><span
lang=EN-GB style='color:black'> </span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>NEOSPHERE is a phase
II, multicentre, multinational randomised controlled trial with Perjeta and was
conducted in 417 adult female patients</span><span lang=EN-GB> </span><span
lang=EN-GB style='color:black'>with newly diagnosed, early, inflammatory or
locally advanced HER2-positive breast cancer (T2-4d</span>; <span lang=EN-GB
style='color:black'>primary tumour &gt; 2cm in diameter) who had not received
prior trastuzumab, chemotherapy or radiotherapy. Patients with metastases,
bilateral breast cancer, clinically important cardiac risk factors (see section
4.4) or LVEF &lt; 55% were not included. The majority of</span><span
lang=EN-GB style='color:black'> patients were </span><span lang=EN-GB
style='color:black'>less than 65 years old. </span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>Patients were </span><span lang=EN-GB style='color:black'>randomised
</span><span lang=EN-GB style='color:black'>to receive</span><span lang=EN-GB
style='color:black'> one of </span><span lang=EN-GB style='color:black'>the
following neoadjuvant regimens for 4 cycles prior to surgery: </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;page-break-after:avoid'><span
style='font-family:Symbol'></span><span lang=EN-GB> <span style='color:
black'>Trastuzumab plus docetaxel </span></span></p>

<p class=MsoNormal style='margin-left:.25in;page-break-after:avoid'><span
style='font-family:Symbol'></span><span lang=EN-GB> <span style='color:
black'>Perjeta plus trastuzumab and docetaxel</span></span></p>

<p class=MsoNormal style='margin-left:.25in'><span style='font-family:Symbol'></span> <span
style='color:black'>Perjeta plus trastuzumab</span></p>

<p class=MsoNormal style='margin-left:.25in'><span style='font-family:Symbol'></span> <span
style='color:black'>Perjeta plus docetaxel. </span></p>

<p class=MsoNormal style='margin-left:.5in'><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Randomisation was
stratified by breast cancer type (operable, locally advanced, or inflammatory)
and ER or PgR positivity.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'> </span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Pertuzumab was given
intravenously at an initial dose of 840 mg, followed by 420 mg every three
weeks. Trastuzumab was given intravenously at an initial dose of 8 mg/kg,
followed by 6 mg/kg every three weeks. Docetaxel was given intravenously at an
initial dose of 75 mg/ m<sup>2</sup> followed by 75 mg/ m<sup>2</sup> or 100
mg/ m<sup>2</sup> (if tolerated) every 3 weeks. Following surgery all patients
received 3 cycles of 5-fluorouracil (600&nbsp;mg/m<sup>2</sup>), epirubicin
(90&nbsp;mg/m<sup>2</sup>), cyclophosphamide (600&nbsp;mg/m<sup>2</sup>) (FEC)
given intravenously every three weeks, and trastuzumab administered
intravenously every three weeks to complete one year of therapy. Patients who
only received Perjeta plus trastuzumab prior to surgery subsequently received
both FEC and docetaxel post surgery.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The primary endpoint of
the study was pathological complete response (pCR) rate in the breast
(ypT0/is). Secondary efficacy endpoints were clinical response rate, breast
conserving surgery rate (T2-3 tumours only), disease-free survival (DFS), and
PFS. Additional exploratory pCR rates included nodal status (ypT0/isN0 and
ypT0N0).</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Demographics were well
balanced (median age was 49-50 years, the majority were caucasian (71%)) and
all patients were female. Overall 7% of patients had inflammatory breast
cancer, 32% had locally advanced breast cancer and 61% had operable breast
cancer. Approximately half the patients in each treatment group had hormone
receptor-positive disease (defined as ER positive and/or PgR positive). </span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>The efficacy results are presented in Table
4. A statistically significant improvement in pCR rate (ypT0/is) was observed
in patients receiving Perjeta plus trastuzumab and docetaxel compared to
patients receiving trastuzumab and docetaxel (45.8% vs 29.0%, p value = </span><span
lang=EN-GB>0.0141</span><span lang=EN-GB>). A consistent pattern of results was
observed regardless of pCR definition. The difference in pCR rate is considered
likely to translate into a clinically meaningful difference in long term
outcomes and is supported by positive trends in PFS (HR 0.69, 95% CI 0.34, 1.40)
and DFS (HR 0.60, 95% CI 0.28, 1.27).<u> </u></span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>The pCR rates as well as the magnitude of
benefit with Perjeta (Perjeta plus trastuzumab and docetaxel compared to
patients receiving trastuzumab and docetaxel) were lower in the subgroup of
patients with hormone receptor-positive tumours (difference of 6% in pCR in the
breast) than in patients with hormone receptor-negative tumours (difference of
26.4% in pCR in the breast).</span><span lang=EN-GB> </span></p>

<p class=MsoNormal><span lang=EN-GB>pCR rates were similar in patients with operable
versus locally advanced disease. There were too few patients with inflammatory
breast cancer to draw any firm conclusions but the pCR rate was higher in
patients who received Perjeta plus trastuzumab and docetaxel.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>TRYPHAENA
(BO22280)</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>TRYPHAENA is
a multicentre, randomised phase II clinical trial conducted in 225 adult female
patients with HER2-positive locally advanced, operable, or inflammatory breast
cancer (T2-4d; primary tumour &gt; 2cm in diameter) who had not received prior
trastuzumab, chemotherapy or radiotherapy. Patients with metastases, bilateral
breast cancer, clinically important cardiac risk factors (see section 4.4) or
LVEF &lt; 55% were not included. The majority of patients were less than 65
years old. Patients were randomised to receive one of three neoadjuvant
regimens prior to surgery as follows: </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
style='font-family:Symbol'></span> <span lang=EN-GB style='color:black'>3
cycles of FEC followed by 3 cycles of docetaxel, all given concurrently with
Perjeta and trastuzumab</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
style='font-family:Symbol'></span> <span lang=EN-GB style='color:black'>3
cycles of FEC alone followed by 3 cycles of docetaxel, with trastuzumab and
Perjeta given concurrently</span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
style='font-family:Symbol'></span> <span lang=EN-GB style='color:black'>6
cycles of TCH in combination with Perjeta. </span></p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Randomisation was stratified by breast
cancer type (operable, locally advanced, or inflammatory) and ER and /or PgR
positivity. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Pertuzumab was given intravenously at an
initial dose of 840 mg, followed by 420 mg every three weeks. Trastuzumab was
given intravenously at an initial dose of 8 mg/kg, followed by 6 mg/kg every
three weeks. FEC (5-fluorouracil [500&nbsp;mg/m<sup>2</sup>], epirubicin [100
mg/m2], cyclophosphamide [600 mg/m2]) were given intravenously every three
weeks for 3 cycles. Docetaxel was given as an initial dose of 75&nbsp;mg/m<sup>2</sup>
IV infusion every three weeks with the option to escalate to 100 mg/m<sup>2</sup>
at the investigators discretion if the initial dose was well tolerated.
However, in the group treated with Perjeta in combination with TCH, docetaxel
was given intravenously at 75&nbsp;mg/m<sup>2</sup> (no escalation was
permitted) and carboplatin (AUC 6) was given intravenously every three weeks.
Following surgery all patients received trastuzumab</span><span lang=EN-GB> to
complete </span><span lang=EN-GB>one year of therapy</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The primary endpoint of this study was
cardiac safety during the neoadjuvant treatment period of the study. Secondary
efficacy endpoints were pCR rate in the breast (ypT0/is), DFS, PFS and OS. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Demographics were well balanced between
arms (median age was 49-50 years, the majority were Caucasian [77%]) and all
patients were female. Overall 6% of patients had inflammatory breast cancer,
25% had locally advanced breast cancer and 69% had operable breast cancer.
Approximately half the patients in each treatment group had ER-positive and/or PgR-positive
disease.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Compared with published data for similar
regimens without pertuzumab, high pCR rates were observed in all 3 treatment arms
(see Table 4). A consistent pattern of results was observed regardless of pCR
definition used. The pCR rates were lower in the subgroup of patients with
hormone receptor-positive tumours (range 46.2% to 50.0%) than in patients with
hormone receptor-negative tumours (range 65.0% to 83.8%).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>pCR rates were similar in patients with
operable and locally advanced disease. There were too few patients with
inflammatory breast cancer to draw any firm conclusions. </span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in;page-break-after:
avoid'><b><span lang=EN-GB style='color:black'>Table 4 NEOSPHERE (WO20697)
and TRYPHAENA (BO22280): Overview of efficacy (Intent to Treat Population) </span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="108%"
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="10%" style='width:10.6%;border:solid windowtext 1.0pt;padding:
   0in 2.85pt 0in 2.85pt'>
   <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
   2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt;color:black'>&nbsp;</span></b></p>
   </td>
   <td width="47%" colspan=4 style='width:47.48%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 2.85pt 0in 2.85pt'>
   <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt;
   color:black'>NEOSPHERE (WO20697)</span></b></p>
   </td>
   <td width="41%" colspan=3 style='width:41.92%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 2.85pt 0in 2.85pt'>
   <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt;
   color:black'>TRYPHAENA (BO22280)</span></b></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width="10%" style='width:10.6%;border:solid windowtext 1.0pt;border-top:
   none;padding:0in 2.85pt 0in 2.85pt'>
   <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
   2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt;color:black'>Parameter</span></b></p>
   </td>
   <td width="11%" style='width:11.44%;border-top:none;border-left:none;
   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 2.85pt 0in 2.85pt'>
   <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt;
   color:black'>Trastuzumab +Docetaxel</span></b></p>
   <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt;
   color:black'>N=107</span></b></p>
   </td>
   <td width="12%" style='width:12.1%;border-top:none;border-left:none;
   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 2.85pt 0in 2.85pt'>
   <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt;
   color:black'>Perjeta+</span></b></p>
   <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt;
   color:black'>Trastuzumab+</span></b></p>
   <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt;
   color:black'>Docetaxel</span></b></p>
   <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt;
   color:black'>N=107</span></b></p>
   </td>
   <td width="12%" style='width:12.12%;border-top:none;border-left:none;
   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 2.85pt 0in 2.85pt'>
   <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt;
   color:black'>Perjeta+</span></b></p>
   <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt;
   color:black'>Trastuzumab</span></b></p>
   <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt;
   color:black'>N=107</span></b></p>
   </td>
   <td width="11%" style='width:11.82%;border-top:none;border-left:none;
   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 2.85pt 0in 2.85pt'>
   <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt;
   color:black'>Perjeta</span></b></p>
   <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt;
   color:black'>+Docetaxel</span></b></p>
   <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt;
   color:black'>N=96</span></b></p>
   </td>
   <td width="13%" style='width:13.72%;border-top:none;border-left:none;
   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 2.85pt 0in 2.85pt'>
   <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:-1.45pt;
   margin-bottom:2.5pt;margin-left:-1.2pt;text-align:center;line-height:12.0pt;
   page-break-after:avoid'><b><span lang=ES style='font-size:10.0pt;color:black'>Perjeta+</span></b></p>
   <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:-1.45pt;
   margin-bottom:2.5pt;margin-left:-1.2pt;text-align:center;line-height:12.0pt;
   page-break-after:avoid'><b><span lang=ES style='font-size:10.0pt;color:black'>Trastuzumab+</span></b></p>
   <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:-1.45pt;
   margin-bottom:2.5pt;margin-left:-1.2pt;text-align:center;line-height:12.0pt;
   page-break-after:avoid'><b><span lang=ES style='font-size:10.0pt;color:black'>FEC</span></b><b><span
   lang=EN-GB style='font-size:10.0pt;font-family:Wingdings;color:black'></span></b></p>
   <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
   page-break-after:avoid'><b><span lang=ES style='font-size:10.0pt;color:black'>Perjeta+</span></b></p>
   <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
   page-break-after:avoid'><b><span lang=ES style='font-size:10.0pt;color:black'>Trastuzumab+</span></b></p>
   <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt;
   color:black'>Docetaxel</span></b></p>
   <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt;
   color:black'>N=73</span></b></p>
   </td>
   <td width="13%" style='width:13.44%;border-top:none;border-left:none;
   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 2.85pt 0in 2.85pt'>
   <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
   page-break-after:avoid'><b><span lang=ES style='font-size:10.0pt;color:black'>FEC</span></b><b><span
   lang=EN-GB style='font-size:10.0pt;font-family:Wingdings;color:black'></span></b></p>
   <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
   page-break-after:avoid'><b><span lang=ES style='font-size:10.0pt;color:black'>Perjeta+</span></b></p>
   <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
   page-break-after:avoid'><b><span lang=ES style='font-size:10.0pt;color:black'>Trastuzumab+</span></b></p>
   <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
   page-break-after:avoid'><b><span lang=ES style='font-size:10.0pt;color:black'>Docetaxel</span></b></p>
   <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
   page-break-after:avoid'><b><span lang=ES style='font-size:10.0pt;color:black'>N=75</span></b></p>
   </td>
   <td width="14%" style='width:14.76%;border-top:none;border-left:none;
   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 2.85pt 0in 2.85pt'>
   <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt;
   color:black'>Perjeta</span></b></p>
   <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt;
   color:black'>+TCH</span></b></p>
   <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt;
   color:black'>N=77</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid;height:48.2pt'>
  <td width="10%" valign=top style='width:10.6%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt;height:48.2pt'>
  <p class=MsoNormal style='margin-top:1.0pt;margin-right:0in;margin-bottom:
  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>pCR rate in the breast
  (ypT0/is)</span></p>
  <p class=MsoNormal style='margin-top:1.0pt;margin-right:0in;margin-bottom:
  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>n (%)</span></p>
  <p class=MsoNormal style='margin-top:1.0pt;margin-right:0in;margin-bottom:
  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>[95% CI]<sup>1</sup></span></p>
  </td>
  <td width="11%" style='width:11.44%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt;height:48.2pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>31
  (29.0%)</span></p>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>[20.6;
  38.5]</span></p>
  </td>
  <td width="12%" style='width:12.1%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt;height:48.2pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>49
  (45.8%)</span></p>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>[36.1;
  55.7]</span></p>
  </td>
  <td width="12%" style='width:12.12%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt;height:48.2pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>18
  (16.8%)</span></p>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>[10.3;
  25.3]</span></p>
  </td>
  <td width="11%" style='width:11.82%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt;height:48.2pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>23
  (24.0%)</span></p>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>[15.8;
  33.7]</span></p>
  </td>
  <td width="13%" style='width:13.72%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt;height:48.2pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>45
  (61.6%)</span></p>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>[49.5;
  72.8]</span></p>
  </td>
  <td width="13%" style='width:13.44%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt;height:48.2pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>43
  (57.3%)</span></p>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>[45.4;
  68.7]</span></p>
  </td>
  <td width="14%" style='width:14.76%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt;height:48.2pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>51
  (66.2%)</span></p>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>[54.6;
  76.6]</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="10%" valign=top style='width:10.6%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Difference in pCR rates<sup>2</sup></span></p>
  <p class=MsoNormal style='margin-top:1.0pt;margin-right:0in;margin-bottom:
  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>[95% CI]<sup>3</sup></span></p>
  </td>
  <td width="11%" style='width:11.44%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="12%" style='width:12.1%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt;color:black'>+16.8 %</span></p>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt;color:black'>[3.5; 30.1]</span></p>
  </td>
  <td width="12%" style='width:12.12%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt;color:black'>-12.2 %</span></p>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:-4.05pt;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;text-indent:-4.1pt;
  line-height:14.0pt;page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>[-23.8; -0.5]</span></p>
  </td>
  <td width="11%" style='width:11.82%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt;color:black'>-21.8 %</span></p>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:-2.8pt;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;text-indent:-1.65pt;
  line-height:14.0pt;page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>[-35.1; -8.5]</span></p>
  </td>
  <td width="13%" style='width:13.72%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>NA</span></p>
  </td>
  <td width="13%" style='width:13.44%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>NA</span></p>
  </td>
  <td width="14%" style='width:14.76%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>NA</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="10%" valign=top style='width:10.6%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:1.0pt;margin-right:0in;margin-bottom:
  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>p-value (with Simes corr. for
  CMH test)<sup>4</sup></span></p>
  </td>
  <td width="11%" style='width:11.44%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="12%" style='width:12.1%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>0.0141</span></p>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>(vs.
  Trastuzumab+Docetaxel)</span></p>
  </td>
  <td width="12%" style='width:12.12%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>0.0198</span></p>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>(vs.
  Trastuzumab+Docetaxel)</span></p>
  </td>
  <td width="11%" style='width:11.82%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>0.0030</span></p>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:-4.45pt;
  margin-bottom:1.0pt;margin-left:-2.8pt;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>(vs
  Perjeta+</span></p>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:-4.45pt;
  margin-bottom:1.0pt;margin-left:-2.8pt;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>Trastuzumab+Docetaxel)</span></p>
  </td>
  <td width="13%" style='width:13.72%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>NA</span></p>
  </td>
  <td width="13%" style='width:13.44%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>NA</span></p>
  </td>
  <td width="14%" style='width:14.76%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>NA</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="10%" valign=top style='width:10.6%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='line-height:14.0pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>pCR rate in the breast and
  lymph node (ypT0/is N0)</span></p>
  <p class=MsoNormal style='margin-bottom:1.0pt;line-height:14.0pt;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>n (%)</span></p>
  <p class=MsoNormal style='margin-top:1.0pt;margin-right:0in;margin-bottom:
  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>[95% CI]</span></p>
  </td>
  <td width="11%" style='width:11.44%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>23
  (21.5%)</span></p>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>[14.1;
  30.5]</span></p>
  </td>
  <td width="12%" style='width:12.1%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>42
  (39.3%)</span></p>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>[30.3;
  49.2]</span></p>
  </td>
  <td width="12%" style='width:12.12%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>12
  (11.2%)</span></p>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>[5.9;
  18.8]</span></p>
  </td>
  <td width="11%" style='width:11.82%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>17
  (17.7%)</span></p>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>[10.7;
  26.8]</span></p>
  </td>
  <td width="13%" style='width:13.72%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>41
  (56.2%)</span></p>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>[44.1;
  67.8]</span></p>
  </td>
  <td width="13%" style='width:13.44%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>41
  (54.7%)</span></p>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>[42.7;
  66.2]</span></p>
  </td>
  <td width="14%" style='width:14.76%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>49
  (63.6%)</span></p>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>[51.9;
  74.3]</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="10%" valign=top style='width:10.6%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:1.0pt;margin-right:0in;margin-bottom:
  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>ypT0 N0 </span></p>
  <p class=MsoNormal style='margin-bottom:1.0pt;line-height:14.0pt;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>n (%)</span></p>
  <p class=MsoNormal style='margin-top:1.0pt;margin-right:0in;margin-bottom:
  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>[95% CI]</span></p>
  </td>
  <td width="11%" style='width:11.44%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>13
  (12.1%)</span></p>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>[6.6;
  19.9]</span></p>
  </td>
  <td width="12%" style='width:12.1%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>35
  (32.7%)</span></p>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>[24.0;
  42.5]</span></p>
  </td>
  <td width="12%" style='width:12.12%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>6
  (5.6%)</span></p>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>[2.1;
  11.8]</span></p>
  </td>
  <td width="11%" style='width:11.82%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>13
  (13.2%)</span></p>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>[7.4;
  22.0]</span></p>
  </td>
  <td width="13%" style='width:13.72%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>37
  (50.7%)</span></p>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>[38.7;
  62.6]</span></p>
  </td>
  <td width="13%" style='width:13.44%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>34
  (45.3%)</span></p>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>[33.8;
  57.3]</span></p>
  </td>
  <td width="14%" style='width:14.76%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>40
  (51.9%)</span></p>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>[40.3;
  63.5]</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="10%" valign=top style='width:10.6%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:1.0pt;margin-right:0in;margin-bottom:
  1.0pt;margin-left:0in;line-height:14.0pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt;color:black'>Clinical Response<sup>5</sup></span></p>
  </td>
  <td width="11%" style='width:11.44%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>79
  (79.8%)</span></p>
  </td>
  <td width="12%" style='width:12.1%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>89
  (88.1%)</span></p>
  </td>
  <td width="12%" style='width:12.12%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>69
  (67.6%)</span></p>
  </td>
  <td width="11%" style='width:11.82%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>65
  (71.4%)</span></p>
  </td>
  <td width="13%" style='width:13.72%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>67
  (91.8%)</span></p>
  </td>
  <td width="13%" style='width:13.44%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>71
  (94.7%)</span></p>
  </td>
  <td width="14%" style='width:14.76%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:1.0pt;margin-right:0in;
  margin-bottom:1.0pt;margin-left:0in;text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>69
  (89.6%)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB style='font-size:10.0pt;color:black'>FEC: 5-fluorouracil,
epirubicin, cyclophosphamide; TCH: docetaxel, carboplatin and trastuzumab, CMH:
CochranMantelHaenszel</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB style='font-size:10.0pt;color:black'>1. 95% CI for one sample
binomial using Pearson-Clopper method.</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB style='font-size:10.0pt;color:black'>2. Treatment Perjeta+Trastuzumab+Docetaxel
and Perjeta+Trastuzumab are compared to Trastuzumab+ Docetaxel while
Perjeta+Docetaxel is compared to Perjeta+Trastuzumab+Docetaxel.</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB style='font-size:10.0pt;color:black'>3. Approximate 95% CI for
difference of two response rates using Hauck-Anderson method.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:10.0pt;color:black'>4. p-value from Cochran-Mantel-Haenszel
test, with Simes multiplicity adjustment.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;color:black'>5.
Clinical response represents patients with a best overall response of CR or PR
during the neoadjuvant period (in the primary breast lesion).</span></p>

<p class=MsoNormal style='margin-left:9.0pt;text-indent:-9.0pt;text-autospace:
none'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>BERENICE
(WO29217)</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal>BERENICE is a non-randomized, open-label, multicentre,
multinational, Phase II trial conducted in 401 patients with HER2-positive
locally advanced, inflammatory, or early-stage breast cancer (with primary
tumours <span style='font-family:Symbol'>&gt;</span>&nbsp;2cm in diameter or
node&#8209;positive disease).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>The BERENICE study included two parallel groups of patients.
Patients considered suitable for neoadjuvant treatment with trastuzumab plus
anthracycline/taxane-based chemotherapy were allocated to receive one of the
two following regimens prior to surgery as follows: </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span>Cohort
A - 4 cycles of two weekly dose-dense doxorubicin and cyclophosphamide followed
by 4 cycles of Perjeta in combination with trastuzumab and paclitaxel.</p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span>Cohort
B - 4 cycles of FEC followed by 4 cycles of Perjeta in combination with trastuzumab
and docetaxel. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Following surgery all patients received Perjeta and
trastuzumab intravenously every 3 weeks to complete 1 year of therapy.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>The primary endpoint of the BERENICE trial is cardiac safety
in the neoadjuvant period of the trial. The primary endpoint of cardiac safety,
i.e. the incidence of NYHA Class III/IV LVD and LVEF declines, was consistent
with previous data in the neoadjuvant setting (see section 4.4. and 4.8).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i>Adjuvant Treatment</i></p>

<p class=MsoNormal><i>&nbsp;</i></p>

<p class=MsoNormal>In the adjuvant setting, based on data from the APHINITY
study, HER2-positive early breast cancer patients at high risk of recurrence
are defined as those with lymph node-positive or hormone receptor-negative
disease.</p>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal><b>APHINITY (BO25126) </b></p>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal>APHINITY is a multicentre, randomised, double-blind,
placebo-controlled Phase III trial conducted in 4804 patients with
HER2-positive early breast cancer who had their primary tumour excised prior to
randomisation. Patients were then randomised to receive Perjeta or placebo, in
combination with adjuvant trastuzumab and chemotherapy. Investigators selected
one of the following anthracycline-based or non-anthracycline-based
chemotherapy regimens for individual patients:</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
style='font-family:Symbol;color:black'></span><span lang=BG style='color:black'> </span>3
or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC),
followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel</p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
style='font-family:Symbol;color:black'></span><span lang=BG style='color:black'> </span>4
cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles
of docetaxel or 12 cycles of weekly paclitaxel </p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
style='font-family:Symbol;color:black'></span><span lang=BG style='color:black'> </span>6
cycles of docetaxel in combination with carboplatin </p>

<p class=MsoNormal style='margin-left:.5in'>&nbsp;</p>

<p class=MsoNormal>Pertuzumab and trastuzumab were administered intravenously
(see section 4.2) every 3 weeks starting<i> </i>on Day 1 of the first
taxane-containing cycle, for a total of 52 weeks (up to 18 cycles) or until
recurrence, withdrawal of consent or unmanageable toxicity. Standard doses of
5-fluorouracil, epirubicin, doxorubicin, cyclophosphamide, docetaxel,
paclitaxel and carboplatin were administered. After completion of chemotherapy,
patients received radiotherapy and/or hormone therapy as per local clinical
standard.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>The primary endpoint of the study was invasive disease-free
survival (IDFS), defined as the time from randomisation to first occurrence of
ipsilateral local or regional invasive breast cancer recurrence, distant
recurrence, contralateral invasive breast cancer, or death from any cause.
Secondary efficacy endpoints were IDFS including second primary non-breast
cancer, overall survival (OS), disease-free survival (DFS), recurrence-free interval
(RFI) and distant recurrence-free interval (DRFI).</p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>Demographics were well
balanced between the two treatment arms. The median age was 51 years, and over
99% of patients were female. The majority of patients had node-positive (63%)
and/or hormone receptor-positive disease (64%), and were Caucasian (71%).</p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>After a median follow-up of
45.4 months, the APHINITY study showed a 19% (hazard ratio [HR] = 0.81; 95% CI
0.66, 1.00 p-value 0.0446) reduction in risk of recurrence or death in patients
randomised to receive Perjeta compared with patients randomised to receive
placebo.</p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>The efficacy results from the
APHINITY trial are summarised in Table 5 and in Figure 3.</p>

<p class=MsoNormal><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in;page-break-after:
avoid'><b>Table 5  Overall Efficacy: ITT Population</b></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in;page-break-after:
avoid'><b>&nbsp;</b></p>

<div align=right>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=610
 style='width:457.35pt;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width=318 valign=bottom style='width:238.5pt;border:solid windowtext 1.0pt;
   padding:0in 2.85pt 0in 2.85pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
   </td>
   <td width=150 valign=bottom style='width:112.5pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 2.85pt 0in 2.85pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Perjeta
   + trastuzumab + Chemotherapy</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>N=2400</span></b></p>
   </td>
   <td width=142 valign=bottom style='width:106.35pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 2.85pt 0in 2.85pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Placebo
   + trastuzumab + Chemotherapy</span></b></p>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>N=2404</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width=318 valign=bottom style='width:238.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB>Primary
  Endpoint</span></i></b></p>
  </td>
  <td width=292 colspan=2 valign=bottom style='width:218.85pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=318 valign=bottom style='width:238.5pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Invasive
  Disease Free Survival (IDFS)<sup> </sup></span></b></p>
  </td>
  <td width=292 colspan=2 valign=bottom style='width:218.85pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=318 valign=bottom style='width:238.5pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Number (%)
  of patients with event </span></p>
  </td>
  <td width=150 valign=bottom style='width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>171 (7.1%)</span></p>
  </td>
  <td width=142 valign=bottom style='width:106.35pt;border:none;border-right:
  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>210 (8.7%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=318 valign=bottom style='width:238.5pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>HR [95%
  CI]</span></p>
  </td>
  <td width=292 colspan=2 valign=bottom style='width:218.85pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.81 [0.66, 1.00]</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=318 valign=bottom style='width:238.5pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>p-value
  (Log-Rank test, stratified<sup>1</sup>)</span></p>
  </td>
  <td width=292 colspan=2 valign=bottom style='width:218.85pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.0446</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=318 valign=bottom style='width:238.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>3 year
  event-free rate<sup>2</sup> [95% CI] </span></p>
  </td>
  <td width=150 valign=bottom style='width:112.5pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>94.1
  [93.1, 95.0]</span></p>
  </td>
  <td width=142 valign=bottom style='width:106.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>93.2 [92.2, 94.3]</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=318 valign=bottom style='width:238.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB>Secondary
  Endpoints<sup>1</sup></span></i></b></p>
  </td>
  <td width=292 colspan=2 valign=bottom style='width:218.85pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=318 valign=bottom style='width:238.5pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>IDFS</span></b><span
  lang=EN-GB> </span><b><span lang=EN-GB>including second primary non-breast
  cancer</span></b></p>
  </td>
  <td width=292 colspan=2 valign=bottom style='width:218.85pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=318 valign=bottom style='width:238.5pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Number (%)
  of patients with event </span></p>
  </td>
  <td width=150 valign=bottom style='width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>189 (7.9%)</span></p>
  </td>
  <td width=142 valign=bottom style='width:106.35pt;border:none;border-right:
  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>230 (9.6%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=318 valign=top style='width:238.5pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>HR [95%
  CI]</span></p>
  </td>
  <td width=292 colspan=2 valign=top style='width:218.85pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.82 [0.68, 0.99]</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=318 valign=bottom style='width:238.5pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>p-value
  (Log-Rank test, stratified<sup>1</sup>)</span></p>
  </td>
  <td width=292 colspan=2 valign=bottom style='width:218.85pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.0430</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=318 valign=bottom style='width:238.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>3 year
  event-free rate<sup>2</sup> [95% CI] </span></p>
  </td>
  <td width=150 valign=bottom style='width:112.5pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>93.5
  [92.5, 94.5]</span></p>
  </td>
  <td width=142 valign=bottom style='width:106.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>92.5 [91.4, 93.6]</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=318 valign=bottom style='width:238.5pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Disease
  Free Survival (DFS) </span></b></p>
  </td>
  <td width=292 colspan=2 valign=bottom style='width:218.85pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=318 valign=bottom style='width:238.5pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Number (%)
  of patients with event</span></p>
  </td>
  <td width=150 valign=bottom style='width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>192 (8.0%)</span></p>
  </td>
  <td width=142 valign=bottom style='width:106.35pt;border:none;border-right:
  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>236 (9.8%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=318 valign=bottom style='width:238.5pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>HR [95%
  CI]</span></p>
  </td>
  <td width=292 colspan=2 valign=bottom style='width:218.85pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.81 [0.67, 0.98]</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=318 valign=bottom style='width:238.5pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>p-value (Log-Rank
  test, stratified<sup>1</sup>)</span></p>
  </td>
  <td width=292 colspan=2 valign=bottom style='width:218.85pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.0327</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=318 valign=bottom style='width:238.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>3 year
  event-free rate<sup>2</sup> [95% CI]</span></p>
  </td>
  <td width=150 valign=bottom style='width:112.5pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>93.4
  [92.4, 94.4]</span></p>
  </td>
  <td width=142 valign=bottom style='width:106.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>92.3 [91.2, 93.4]</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:6.1pt'>
  <td width=318 valign=bottom style='width:238.5pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt;height:6.1pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Overall
  Survival (OS)<sup>3</sup></span></b></p>
  </td>
  <td width=292 colspan=2 valign=bottom style='width:218.85pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:
  6.1pt'>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:10.9pt'>
  <td width=318 valign=bottom style='width:238.5pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt;height:10.9pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Number (%)
  of patients with event</span></p>
  </td>
  <td width=150 valign=bottom style='width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt;
  height:10.9pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>80 (3.3%)</span></p>
  </td>
  <td width=142 valign=bottom style='width:106.35pt;border:none;border-right:
  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:10.9pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>89 (3.7%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:10.9pt'>
  <td width=318 valign=bottom style='width:238.5pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt;height:10.9pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>HR [95%
  CI]</span></p>
  </td>
  <td width=292 colspan=2 valign=bottom style='width:218.85pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:
  10.9pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.89 [0.66, 1.21]</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:10.9pt'>
  <td width=318 valign=bottom style='width:238.5pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt;height:10.9pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>p-value
  (Log-Rank test, stratified<sup>1</sup>)</span></p>
  </td>
  <td width=292 colspan=2 valign=bottom style='width:218.85pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:
  10.9pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.4673</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:10.9pt'>
  <td width=318 valign=bottom style='width:238.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt;height:10.9pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>3 year
  event-free rate<sup>2</sup> [95% CI]</span></p>
  </td>
  <td width=150 valign=bottom style='width:112.5pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:10.9pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>97.7
  [97.0, 98.3]</span></p>
  </td>
  <td width=142 valign=bottom style='width:106.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt;height:10.9pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>97.7 [97.1, 98.3]</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal style='page-break-after:avoid'><b><span style='font-size:
10.0pt'>Key to abbreviations (Table 5): </span></b><span lang=EN-GB
style='font-size:10.0pt'>HR: Hazard Ratio; CI: Confidence Interval </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='font-size:10.0pt'>1.
All analyses stratified by nodal status, protocol version, central hormone
receptor status, and adjuvant chemotherapy
regimen. </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='font-size:10.0pt'>2.
3-year event-free rate derived from Kaplan-Meier estimates.</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in;page-break-after:
avoid'><span style='font-size:10.0pt'>3. Data from first interim analysis. </span></p>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in;page-break-after:
avoid'><b>Figure 3 Kaplan-Meier Curve of Invasive Disease Free Survival </b></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in;page-break-after:
avoid'><b>&nbsp;</b></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='font-size:8.0pt'><img
border=0 width=604 height=385 id="Picture 8"
src="Perjeta-II-48%20EN%20PI%20clean_files/image004.png"></span></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='font-size:8.0pt'>IDFS=
invasive disease free survival; CI= confidence interval; Pla= placebo; Ptz=
pertuzumab (Perjeta); T= trastuzumab.</span></p>

<p class=MsoNormal style='margin-bottom:10.0pt;line-height:115%'><span
style='line-height:115%'>&nbsp;</span></p>

<p class=MsoNormal>The estimate of IDFS at 4-years was 92.3% in the
Perjeta-treated group versus 90.6% in the placebo-treated group. At the time of
the estimate the median follow-up was 45.4 months.</p>

<p class=MsoNormal><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal><u>Results of Subgroup Analysis </u></p>

<p class=MsoNormal><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal>At the time of the primary analysis, the benefits of Perjeta
were more apparent in subgroups of patients a high risk of recurrence: patients
with node-positive or hormone receptor-negative disease (see table 6).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><b><u>Table&nbsp;6 Efficacy
results in subgroups by nodal status and hormone receptor status<sup>1</sup></u></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><u><span style='text-decoration:
 none'>&nbsp;</span></u></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=614
 style='width:460.25pt;border-collapse:collapse;border:none'>
 <tr style='height:11.1pt'>
  <td width=169 rowspan=2 valign=top style='width:126.9pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.1pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Population</span></b></p>
  </td>
  <td width=311 colspan=2 valign=top style='width:232.9pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:11.1pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Number
  of IDFS events/Total N (%)</span></b></p>
  </td>
  <td width=134 rowspan=2 valign=top style='width:100.45pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:11.1pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Unstratified
  HR (95% CI)</span></b></p>
  </td>
 </tr>
 <tr style='height:44.95pt'>
  <td width=151 valign=top style='width:113.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:44.95pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Perjeta + trastuzumab + chemotherapy</span></b></p>
  </td>
  <td width=159 valign=top style='width:119.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:44.95pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Placebo + <br>
  trastuzumab + chemotherapy</span></b></p>
  </td>
 </tr>
 <tr style='height:11.65pt'>
  <td width=614 colspan=4 valign=top style='width:460.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.65pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Nodal
  status</span></b></p>
  </td>
 </tr>
 <tr style='height:26.75pt'>
  <td width=169 valign=top style='width:126.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:26.75pt'>
  <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;&nbsp; Positive</span></p>
  </td>
  <td width=151 valign=top style='width:113.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>139/1503</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(9.2%)</span></p>
  </td>
  <td width=159 valign=top style='width:119.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>181/1502</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(12.1%)</span></p>
  </td>
  <td width=134 valign=top style='width:100.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.77</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(0.62, 0.96)</span></p>
  </td>
 </tr>
 <tr style='height:23.3pt'>
  <td width=169 valign=top style='width:126.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.3pt'>
  <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;&nbsp; Negative </span></p>
  </td>
  <td width=151 valign=top style='width:113.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.3pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>32/897</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(3.6%)</span></p>
  </td>
  <td width=159 valign=top style='width:119.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.3pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>29/902</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(3.2%)</span></p>
  </td>
  <td width=134 valign=top style='width:100.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.3pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>1.13</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(0.68, 1.86)</span></p>
  </td>
 </tr>
 <tr style='height:11.25pt'>
  <td width=169 valign=top style='width:126.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.25pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Hormone
  receptor status</span></b></p>
  </td>
  <td width=151 valign=top style='width:113.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.25pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=159 valign=top style='width:119.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.25pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=134 valign=top style='width:100.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.25pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:26.75pt'>
  <td width=169 valign=top style='width:126.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:26.75pt'>
  <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;&nbsp; Negative</span></p>
  </td>
  <td width=151 valign=top style='width:113.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>71/864</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(8.2%)</span></p>
  </td>
  <td width=159 valign=top style='width:119.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>91/858</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(10.6%)</span></p>
  </td>
  <td width=134 valign=top style='width:100.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.76</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(0.56, 1.04)</span></p>
  </td>
 </tr>
 <tr style='height:26.75pt'>
  <td width=169 valign=top style='width:126.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:26.75pt'>
  <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;&nbsp; Positive</span></p>
  </td>
  <td width=151 valign=top style='width:113.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>100/1536</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(6.5%)</span></p>
  </td>
  <td width=159 valign=top style='width:119.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>119/1546</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(7.7%)</span></p>
  </td>
  <td width=134 valign=top style='width:100.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.86</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(0.66, 1.13)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='page-break-after:avoid'><sup><span style='font-size:
10.0pt'>1</span></sup><span style='font-size:10.0pt'> Prespecified subgroup
analyses without adjusting for multiple comparisons, therefore, results are
considered descriptive.</span></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>Estimates of IDFS rates in
the lymph node- positive subgroup were 92.0% versus 90.2% at 3&nbsp;years and
89.9% vs. 86.7% at 4 years in Perjeta-treated patients versus placebo-treated
patients, respectively. In the lymph node- negative subgroup, estimates of IDFS
rates were 97.5% versus 98.4% at 3&nbsp;years and 96.2% versus 96.7% at 4 years
in Perjeta-treated patients versus placebo-treated patients, respectively. In
the hormone receptor-negative subgroup, estimates of IDFS rates were 92.8%
versus 91.2% at 3 years and 91.0% versus 88.7% at 4 years in Perjeta-treated
patients versus placebo-treated patients, respectively. In the hormone
receptor-positive subgroup estimates of IDFS rates were 94.8% versus 94.4% at 3
years and 93.0% versus 91.6% at 4 years in Perjeta-treated patients versus
placebo-treated patients, respectively. </p>

<p class=MsoNormal style='page-break-after:avoid'><b><u><span style='text-decoration:
 none'>&nbsp;</span></u></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Patient
Reported Outcomes (PRO)</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Secondary
endpoints included the assessment of patient-reported global health status,
role and physical function, and treatment symptoms using the EORTC QLQ-C30 and
EORTC QLQ-BR23 questionnaires. In the analyses of patient-reported outcomes, a
10-point difference was considered clinically meaningful. </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Patients
physical function, global health status and diarrhoea scores showed a
clinically meaningful change during chemotherapy in both treatment arms. The
mean decrease from baseline at that time for physical function was -10.7 (95%
CI-11.4, -10.0) in the Perjeta arm and -10.6 (95% CI -11.4, -9.9) in the
placebo arm; global health status was -11.2 (95% CI -12.2, -10.2) in the
Perjeta arm and -10.2 (95% CI -11.1,-9.2) in the placebo arm. Change in
diarrhoea symptoms increased to +22.3 (95% CI 21.0, 23.6) in the Perjeta arm
versus +9.2 (95% CI 8.2, 10.2) in the placebo arm. </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Thereafter
in both arms physical function and global health status scores returned to
baseline levels during targeted treatment. Diarrhoea symptoms returned to
baseline after HER2 therapy in the Perjeta-arm. The addition of Perjeta to
trastuzumab plus chemotherapy did not affect patients overall role function
over the course of the study. </span></p>

<p class=MsoNormal style='margin-left:9.0pt;text-indent:-9.0pt;text-autospace:
none'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Immunogenicity</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients in the pivotal trial CLEOPATRA
were tested at multiple time-points for </span><span lang=EN-GB>anti-drug antibodies
(ADA</span><span lang=EN-GB>) to </span><span lang=EN-GB>Perjeta. </span><span
lang=EN-GB>3.3% (13/389 patients) of Perjeta-treated patients and 6.7% (25/372
patients) of placebo-treated patients tested positive for ADA. </span>In BERENICE,
4.1% (16/392) of the patients treated with Perjeta tested positive for ADA. <span
lang=EN-GB>None of these patients experienced anaphylactic/hypersensitivity
reactions that were clearly related to ADA.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Paediatric
population</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The European Medicines Agency has waived
the obligation to submit the results of studies with </span><span lang=EN-GB>Perjeta
</span><span lang=EN-GB>in all subsets of the paediatric population in </span><span
lang=EN-GB>breast cancer</span><span lang=EN-GB> (see section 4.2 for
information on paediatric use).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>5.2 Pharmacokinetic properties</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>A population pharmacokinetic analysis was
performed with data from 481 patients across different clinical trials (phase
I, II and III) with various types of advanced malignancies who had received Perjeta
as a single agent or in combination at pertuzumab doses ranging from 2 to 25&nbsp;mg/kg
administered every 3 weeks as a 30-60 minutes intravenous infusion.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Absorption</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Perjeta is administered as an intravenous
infusion. </span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Distribution</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Across all clinical studies, the volume of
distribution of the central (Vc) and the peripheral (Vp) compartment in the
typical patient, was 3.11&nbsp;litres and 2.46&nbsp;litres, respectively.</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><u><span lang=EN-GB>Biotransformation</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The metabolism of pertuzumab has not been directly
studied. Antibodies are cleared principally by catabolism.</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><u><span lang=EN-GB>Elimination</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The median clearance (CL) of pertuzumab was
0.235&nbsp;litres/day and the median half-life was 18 days.</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><u><span lang=EN-GB>Linearity/non-linearity</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Pertuzumab displayed linear
pharmacokinetics within the recommended dose range.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Elderly patients</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Based on the population
pharmacokinetic analysis, no significant difference was observed in the
pharmacokinetics of pertuzumab between patients &lt;&nbsp;65 years (n=306) and
patients &#8805;&nbsp;65 years (n=175).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Renal impairment </span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No dedicated renal impairment trial for Perjeta
has been conducted. Based on the results of the population pharmacokinetic
analysis, pertuzumab exposure in patients with mild (creatinine clearance
[CLcr] 60 to 90&nbsp;ml/min, N=200) and moderate renal impairment (CLcr 30 to
60&nbsp;ml/min, N=71) was similar to that in patients with normal renal
function (CLcr greater than 90&nbsp;ml/min, N=200). No relationship between
CLcr and pertuzumab exposure was observed over the range of CLcr (27 to 244&nbsp;ml/min).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Other special populations</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The population PK analysis suggested no PK
differences based on age, gender and ethnicity (Japanese versus non-Japanese).
Baseline albumin and lean body weight were the most significant covariates
influencing CL. CL decreased in patients with higher baseline albumin
concentrations and increased in patients with greater lean body weight. However
sensitivity analyses performed at the recommended dose and schedule of Perjeta
showed that at the extreme values of these two covariates, there was no
significant impact on the ability to achieve target steady-state concentrations
identified in preclinical tumour xenograft models. Therefore, there is no need
to adjust the dosage of pertuzumab based on these covariates.</span></p>

<p class=MsoNormal><span lang=EN-GB></span></p>

<p class=MsoNormal><span lang=EN-GB>The PK results of pertuzumab in the
NEOSPHERE and APHINITY studies were consistent with the predictions from the
previous population PK model. </span>No differences in pertuzumab PK were
observed in patients with early breast cancer compared to patients with
metastatic breast cancer.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><b><span
lang=EN-GB>5.3 Preclinical safety data</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No specific fertility studies in animals
have been performed to evaluate the effect of pertuzumab. No definitive
conclusion on adverse effects can be drawn on the male reproductive organs in
cynomolgus monkey repeated dose toxicity study.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Reproductive toxicology studies have been
conducted in pregnant cynomolgus monkeys (Gestational Day (GD) 19 through to GD
50) at initial doses of 30 to 150&nbsp;mg/kg followed by bi&#8209;weekly doses
of 10&nbsp;to&nbsp;100&nbsp;mg/kg. These dose levels resulted in clinically
relevant exposures of 2.5&nbsp;to&nbsp;20-fold greater than the recommended
human dose, based on C<sub>max</sub>. Intravenous administration of pertuzumab from
GD19 through GD50 (period of organogenesis) was embryotoxic, with
dose-dependent increases in embryo-foetal death between GD25&nbsp;to&nbsp;GD70.
The incidences of embryo-foetal loss were 33, 50, and 85% for pregnant female
monkeys treated with bi&#8209;weekly pertuzumab doses of 10, 30, and
100&nbsp;mg/kg, respectively (2.5&nbsp;to&nbsp;20-fold greater than the
recommended human dose, based on C<sub>max</sub>). At Caesarean section on
GD100, oligohydramnios, decreased relative lung and kidney weights and
microscopic evidence of renal hypoplasia consistent with delayed renal
development were identified in all pertuzumab dose groups. In addition,
consistent with foetal growth restrictions, secondary to oligohydramnios, lung
hypoplasia (1 of 6 in 30&nbsp;mg/kg and 1 of 2 in100&nbsp;mg/kg groups),
ventricular septal defects (1 of 6 in 30&nbsp;mg/kg group), thin ventricular
wall (1 of 2 in 100&nbsp;mg/kg group) and minor skeletal defects (external - 3
of 6 in 30&nbsp;mg/kg group) were also noted. Pertuzumab exposure was reported
in offspring from all treated groups, at levels of 29% to 40% of maternal serum
levels at GD100. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In cynomolgus monkeys, weekly intravenous
administration of </span><span lang=EN-GB>pertuzumab </span><span lang=EN-GB>at
doses up to 150&nbsp;mg/kg/dose was generally well tolerated. With doses of
15&nbsp;mg/kg and higher, intermittent mild treatment-associated diarrhoea was
noted. In a subset of monkeys, chronic dosing (7 to 26 weekly doses) resulted in
episodes of severe secretory diarrhoea. The diarrhoea was managed (with the
exception of euthanasia of one animal, 50&nbsp;mg/kg/dose) with supportive care
including intravenous fluid replacement therapy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>6. PHARMACEUTICAL PARTICULARS</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>6.1 List of excipients</span></b></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Glacial acetic acid</span></p>

<p class=MsoNormal><span lang=EN-GB>L-Histidine</span></p>

<p class=MsoNormal><span lang=EN-GB>Sucrose</span></p>

<p class=MsoNormal><span lang=EN-GB>Polysorbate 20</span></p>

<p class=MsoNormal><span lang=EN-GB>Water for injections</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>6.2 Incompatibilities</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Glucose (5%)
solution should not be used to dilute Perjeta since it is chemically and
physically unstable in such solutions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>This medicinal product must not be mixed
with other medicinal products except those mentioned in section 6.6.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>6.3 Shelf life</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB
style='color:black'>Unopened vial</span></u><span lang=EN-GB style='color:black'>
</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>2 years</span><span lang=EN-GB style='color:black'>. </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Diluted solution</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Chemical and physical in-use stability has
been demonstrated for 24 hours at 30C. </span></p>

<p class=MsoNormal><span lang=EN-GB>From a microbiological point of view, the
product should be used immediately. If not used immediately, in-use storage
times and conditions prior to use are the responsibility of the user and would
normally not be longer than 24 hours at 2C to 8C, unless dilution has taken
place in controlled and validated aseptic conditions.</span><span lang=EN-GB> </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>6.4 Special precautions for
storage</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Store in a refrigerator (2C-8C).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not freeze. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep the vial in the outer carton in order
to protect from light.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For storage conditions after dilution of
the medicinal product, see section 6.3.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>6.5 Nature and contents of
container</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Vial (Type I glass) with a stopper (butyl
rubber) containing 14&nbsp;ml of solution. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Pack of 1 vial.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><a name="OLE_LINK1"><b><span
lang=EN-GB>6.6 Special precautions for disposal and other handling</span></b></a></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Perjeta does
not contain any antimicrobial preservative. Therefore, care must be taken to
ensure the sterility of the prepared solution for infusion and should be
prepared by a healthcare professional. </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Perjeta is
for single use only.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The vial
must not be shaken. 14 ml of Perjeta concentrate should be withdrawn from the
vial and diluted into a 250&nbsp;ml PVC or non-PVC polyolefin infusion bag of
sodium chloride 9&nbsp;mg/ml (0.9%) solution for infusion. After dilution, one
ml of solution should contain approximately </span><span lang=EN-GB>3.02&nbsp;mg
of pertuzumab (840&nbsp;mg/278&nbsp;ml) for the initial dose where two vials
are required and approximately 1.59&nbsp;mg of pertuzumab (420&nbsp;mg/264 &nbsp;ml)
for the maintenance dose where one vial is required. </span></p>

<p class=MsoNormal><span lang=EN-GB>The bag should be gently inverted to mix
the solution in order to avoid foaming.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Parenteral medicinal products should be
inspected visually for particulates and discolouration prior to administration.
If particulates or discoloration are observed, the solution should not be used.
Once the infusion is prepared it should be administered immediately (see
section 6.3). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Any unused medicinal product or waste
material should be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Perjeta is compatible with
polyvinylchloride (PVC) or non-PVC polyolefin bags including polyethylene.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>7.</span></b><span
lang=EN-GB> <b>MARKETING AUTHORISATION HOLDER</b></span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Roche Registration GmbH </span></p>

<p class=MsoNormal><span lang=EN-GB>Emil-Barell-Strasse 1</span></p>

<p class=MsoNormal><span lang=EN-GB>79639 Grenzach-Wyhlen</span></p>

<p class=MsoNormal><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>8. MARKETING
AUTHORISATION NUMBER(S) </span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/13/813/001</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>9. DATE OF FIRST
AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Date of first authorisation: 4<sup>th</sup>
March 2013</span></p>

<p class=MsoNormal><span lang=EN-GB>Date of latest renewal: 8<sup>th</sup>
December 2017</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>10. DATE
OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Detailed
information on this medicinal product </span><span lang=EN-GB>is available on
the website of the European Medicines Agency </span><a
href="http://www.ema.europa.eu"><span lang=EN-GB>http://www.ema.europa.eu</span></a><span
lang=EN-GB style='color:blue'>.</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX</span></b><b><span
lang=EN-GB> II</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.9pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt'><b><span
lang=EN-GB>A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND
MANUFACTURER RESPONSIBLE FOR BATCH RELEASE </span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.9pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.9pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt'><b><span
lang=EN-GB>B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.9pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.9pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt'><b><span
lang=EN-GB>C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING
AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.9pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.9pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt'><b><span
lang=EN-GB>D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND
EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=AnnexHeading><span lang=EN-GB>A. </span><span lang=EN-GB>MANUFACTURER
OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH
RELEASE</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:10.0pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><u><span
lang=EN-GB>Name and address of the manufacturer of the biological active
substance(s) </span></u></p>

<p class=MsoNormal><span lang=EN-GB>Genentech, Inc.</span></p>

<p class=MsoNormal><span lang=EN-GB>1000 New Horizons Way</span></p>

<p class=MsoNormal><span lang=EN-GB>Vacaville, CA 95688-9431</span></p>

<p class=MsoNormal><span lang=EN-GB>USA</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><u><span
lang=EN-GB>Name and address of the manufacturer responsible for batch release</span></u></p>

<p class=MsoNormal><span lang=DE-CH>Roche Pharma AG</span></p>

<p class=MsoNormal><span lang=DE-CH>Emil-Barell-Strasse 1</span></p>

<p class=MsoNormal><span lang=EN-GB>D-79639 Grenzach-Whylen</span></p>

<p class=MsoNormal><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal style='line-height:10.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:10.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=AnnexHeading><span lang=EN-GB>B. CONDITIONS OR RESTRICTIONS
REGARDING SUPPLY AND USE</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Medicinal product subject to restricted
medical prescription (see Annex I: Summary of Product Characteristics, section
4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:10.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=AnnexHeading><span lang=EN-GB>C.  OTHER CONDITIONS AND
REQUIREMENTS OF THE MARKETING AUTHORISATION </span></p>

<p class=MsoNormal style='line-height:10.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:13.0pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><b><span
lang=EN-GB>Periodic safety update reports </span></b></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:13.0pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:14.0pt'>The requirements for submission
of periodic safety update reports for this medicinal product are <span
lang=EN-GB>set out in the list of Union reference dates (EURD list) provided
for under Article 107c(7) of Directive 2001/83/EC and any subsquent updates published
on the European medicines web-portal.</span></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:13.0pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:13.0pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=AnnexHeading><span lang=EN-GB>D. CONDITIONS OR RESTRICTIONS WITH
REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:11.0pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:13.0pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><b><span
lang=EN-GB>Risk Management Plan (RMP)</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt;line-height:13.0pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:13.0pt'><span
lang=EN-GB>The MAH shall perform the required pharmacovigilance activities and
interventions detailed in the agreed RMP presented in Module 1.8.2 of the
Marketing Authorisation and any agreeed subsequent updates of the RMP.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:13.0pt'><span
lang=EN-GB>An updated RMP should be submitted:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:14.2pt;margin-bottom:.0001pt;line-height:13.0pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>At the request of the European Medicines Agency;</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-12.8pt;line-height:
13.0pt'><span lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> Whenever
the risk management system is modified, especially as the result of new
information being received that may lead to a significant change to the
benefit/risk profile or as the result of an important (pharmacovigilance or
risk minimisation) milestone being reached. </span></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:13.0pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:13.0pt;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> </span><b><span
lang=EN-GB>Obligation to conduct post-authorisation measures</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:13.0pt;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:13.0pt;page-break-after:
avoid'><span lang=EN-GB>The MAH shall complete, within the stated timeframe,
the following measures:</span></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:13.0pt;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="98%"
 style='width:98.0%;border-collapse:collapse;border:none'>
 <tr>
  <td width="83%" valign=top style='width:83.62%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.05pt'><b><span lang=EN-GB>Description</span></b></p>
  </td>
  <td width="16%" valign=top style='width:16.38%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText><b><span lang=EN-GB style='color:windowtext;font-style:
  normal'>Due date</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="83%" valign=top style='width:83.62%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:14.0pt'><span lang=EN-GB>MO28047
  (PERUSE) </span></p>
  <p class=MsoNormal style='line-height:14.0pt'><span lang=EN-GB>A multicenter,
  open-label, single-arm study of pertuzumab in combination with trastuzumab
  and a taxane in first line treatment of patients with HER2- positive advanced
  (metastatic or locally recurrent) breast cancer</span></p>
  <p class=MsoNormal style='line-height:14.0pt'><span lang=EN-GB
  style='font-size:9.0pt;font-family:"Verdana",sans-serif'>&nbsp;</span></p>
  </td>
  <td width="16%" valign=top style='width:16.38%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:14.0pt'><span lang=EN-GB>September 2020</span></p>
  </td>
 </tr>
</table>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX
III</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>LABELLING
AND PACKAGE LEAFLET</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=Annex><span lang=EN-GB>A. LABELLING</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>CARTON</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Perjeta 420&nbsp;mg concentrate for
solution for infusion</span></p>

<p class=MsoNormal><span lang=EN-GB>pertuzumab</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>One 14&nbsp;ml vial contains 420&nbsp;mg of
pertuzumab at a concentration of 30&nbsp;mg/ml.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>3. LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Glacial acetic acid, L-histidine, sucrose
and polysorbate 20.</span></p>

<p class=MsoNormal><span lang=EN-GB>Water for injections</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Concentrate for solution for infusion</span></p>

<p class=MsoNormal><span lang=EN-GB>420&nbsp;mg/14&nbsp;ml</span></p>

<p class=MsoNormal><span lang=EN-GB>1 x 14&nbsp;ml</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>5. METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For intravenous use after dilution</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not shake</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;border:none;
padding:0in'><b><span lang=EN-GB>6. SPECIAL WARNING THAT THE MEDICINAL
PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of children</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>7. OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>9. SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Store in a
refrigerator</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Do not
freeze</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep the vial in the outer carton in order
to protect from light </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;border:none;
padding:0in'><b><span lang=EN-GB>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=DE-CH>Roche Registration GmbH </span></p>

<p class=MsoNormal><span lang=DE-CH>Emil-Barell-Strasse 1</span></p>

<p class=MsoNormal><span lang=DE>79639 Grenzach-Wyhlen</span></p>

<p class=MsoNormal><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING
AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/13/813/001</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>13. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Batch</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Medicinal product subject to medical
prescription</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>16. INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black;background:#D9D9D9'>Justification
for not including Braille accepted</span> </p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b>17. UNIQUE
IDENTIFIER  2D BARCODE</b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span style='background:lightgrey'>2D barcode carrying the
unique identifier included.</span></p>

<p class=MsoNormal><span style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b>18. UNIQUE
IDENTIFIER - HUMAN READABLE DATA</b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>PC: </p>

<p class=MsoNormal>SN: </p>

<p class=MsoNormal>NN: </p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>MINIMUM
PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>VIAL
LABEL</span></b></p>

</div>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Perjeta 420&nbsp;mg concentrate for
solution for infusion</span></p>

<p class=MsoNormal><span lang=EN-GB>pertuzumab</span></p>

<p class=MsoNormal><span style='color:black;background:#D9D9D9'>IV</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For intravenous use after dilution</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>420&nbsp;mg/14&nbsp;ml</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=Annex><span lang=EN-GB>B. PACKAGE LEAFLET</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>Package
Leaflet: Information for the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>Perjeta
420&nbsp;mg concentrate for solution for infusion</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>pertuzumab</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:12.0pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Read all of this leaflet carefully
before you start being given this medicine because it contains important
information for you.</span></b></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> Keep
this leaflet. You may need to read it again.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> If you
have any further questions, ask your doctor or nurse. </span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> If you
get any side effects, talk to your doctor or nurse. This includes any possible
side effects not listed in this leaflet. See section 4.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>What is in this leaflet</span></b><span
lang=EN-GB>: </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>1. What Perjeta<b> </b>is and what it is used for</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>2. What you need to know before you are given Perjeta</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>3. How you are given Perjeta </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>4. Possible side effects</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>5. How to store Perjeta</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>6. Contents of the pack and other information</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>1. What Perjeta is and what it
is used for</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Perjeta contains the active substance
pertuzumab and is used to treat adult patients with breast cancer when:</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> The breast cancer
has been identified to be of the HER2-positive form  your doctor will test
you for this.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> The cancer has
spread to other parts of the body such as the lungs or liver (metastasised) and
has not previously been treated with anticancer medicines (chemotherapy) or
other medicines designed to attach to HER2, or else the cancer has come back in
the breast after previous treatment.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> The cancer has
not spread to other parts of the body and treatment is going to be given before
surgery takes place (treatment before surgery is called neoadjuvant therapy)</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> The cancer has
not spread to other parts of the body and treatment is going to be given after
surgery (treatment after surgery is called adjuvant therapy)</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>As well as Perjeta you will also receive trastuzumab
and medicines called chemotherapy Information about these medicines is
described in separate package leaflets. Ask your doctor or nurse to give you
information about these other medicines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>How Perjeta
works</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Perjeta is a
type of medicine called a monoclonal antibody which attaches itself to
specific targets in your body and on the cancer cells.<b> </b></span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Perjeta
recognises and attaches to a target called human epidermal growth factor&nbsp;receptor
2 (HER2). HER2 is found in large amounts on the surface of some cancer cells
where it stimulates their growth. When Perjeta attaches to the HER2 cancer
cells, it may slow or stop the cancer cells from growing, or may kill them.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>2. What
you need to know before you are given Perjeta</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>You must
not be given Perjeta</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> If you are
allergic to pertuzumab, or to any of the other ingredients of this medicine
(listed in section 6).</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you are not sure, talk to your doctor or
nurse before you are given Perjeta.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Warnings
and precautions</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Treatment with Perjeta may affect the heart.
Talk to your doctor or nurse before you are given Perjeta:</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> If you have ever
had heart problems (such as heart failure, treatment for serious irregular
heartbeats, uncontrolled high blood pressure, recent heart attack), your heart
function will be checked before and during treatment with Perjeta and your
doctor will run tests to check if your heart is working properly. </span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> If you have ever
had heart problems during previous treatment with trastuzumab.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> If you have ever
had a chemotherapy medicine from the class called anthracyclines, e.g.
doxorubicin or epirubicin  these medicines can damage heart muscle and
increase the risk of heart problems with Perjeta.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If any of the above applies to you (or you
are not sure), talk to your doctor or nurse before you are given Perjeta. See
section 4 Serious side effects for more details about signs of heart problems
to look out for.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Infusion reactions</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Infusion reactions, allergic or
anaphylactic (more severe allergic) reactions can happen. Your doctor or nurse
will check for side effects during your infusion and for 30 to 60 minutes
afterwards. If you get any serious reaction, your doctor may stop treatment
with Perjeta. Very rarely, patients have died due to anaphylactic reactions
during Perjeta infusion. See section 4 Serious side effects for more details
about infusion reactions to look out for during the infusion and thereafter. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Febrile neutropenia (Low white blood
cells with fever)</span></u></p>

<p class=MsoNormal><span lang=EN-GB>When Perjeta is given with other cancer
treatments (trastuzumab and chemotherapy), the number of white blood cells may
drop and fever (raised temperature) may develop. If you have inflammation of
the digestive tract (e.g.sore mouth or diarrhoea) you may be more likely to
develop this side effect.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Diarrhoea</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Treatment with Perjeta may cause severe
diarrhoea. Patients over 65&nbsp;years of age have a higher risk of diarrhoea compared
with patients younger than 65 years of age.</span><span lang=EN-GB
style='color:black;background:white'> </span><span lang=EN-GB>Diarrhoea is a
condition where your body produces more watery stools than normal. If you
experience severe diarrhoea while receiving your anti-cancer treatment, your
doctor may start you on anti-diarrhoeal treatment and may stop your treatment
with Perjeta until the diarrhoea is under control. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Use in children and adolescents</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Perjeta should not be given to patients under
the age of 18 years because there is no information on how it works in this age
group.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><b><span lang=EN-GB
style='color:black'>Use in the elderly</span></b></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Patients
over 65&nbsp;years of age who are treated with Perjeta are more likely to
experience side effects such as reduced appetite, decrease in the number of red
blood cells, weight loss, feeling tired, loss or altered taste, weak, numb,
tingling or prickling sensations mainly affecting the feet and legs and
diarrhoea, compared to patients younger than 65&nbsp;years of age.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Other medicines and Perjeta</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Tell your doctor or nurse if you are
taking, have recently taken or might take any other medicines. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Pregnancy
and breast-feeding</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Before starting treatment, you must tell
your doctor or nurse if you are pregnant or breast-feeding, </span><span
lang=EN-GB>or if you </span><span lang=EN-GB>think you may be pregnant<b> </b>or
are planning to have a baby. They will advise you about the benefits and risks
for you and your baby of taking Perjeta while you are pregnant.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> Tell your doctor
straight away,<b> </b>if you get pregnant during treatment with<b> </b>Perjeta
or during the 6 months after stopping treatment.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> Ask your doctor
about whether you can breast-feed during or after treatment with Perjeta.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Perjeta may harm the unborn baby. You
should use effective contraception during treatment with Perjeta and for 6 months
after stopping treatment. Talk to your doctor about the best contraception for
you.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Driving and using machines</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Perjeta may have a minor effect on you
being able to drive or use machines. However, if you get any dizziness, infusion
reactions, allergic or anaphylactic reactions, wait until these have gone away
before driving or using machines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b>Sodium</b> </p>

<p class=MsoNormal>Perjeta contains less than 1&nbsp;mmol of sodium per dose,
i.e. it is essentially sodium&#8209;free.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>3. How
you are given Perjeta</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Being
given this medicine</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><span
lang=EN-GB>Perjeta</span><span lang=EN-GB> will be given to you by a doctor or
nurse in a hospital or clinic.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> It is given by a
drip into a vein (intravenous infusion) once every three weeks.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> The amount of
medicine you are given and how long the infusion will last are different for
the first dose and following doses. </span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> The number of
infusions you will be given depends on how you respond to treatment</span><span
lang=EN-GB> and whether you are receiving treatment before or after surgery
(neoadjuvant or adjuvant therapy) or for disease which has spread</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB> Perjeta is given with other cancer treatments (trastuzumab
andchemotherapy).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>For the</span></b><span lang=EN-GB> <b>first
infusion</b>:</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> You will be given
840&nbsp;mg of Perjeta over 60 minutes. Your doctor or nurse will check for
side effects during your infusion and for 60 minutes afterwards.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> You will also be
given trastuzumab and chemotherapyl.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>For all
following infusions</span></b><span lang=EN-GB>, if the first infusion was well
tolerated:</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> You
will be given 420&nbsp;mg of Perjeta over 30 to 60 minutes. Your doctor or
nurse will check for side effects during your infusion and for 30 to 60 minutes
afterwards.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> You
will also be given trastuzumab and chemotherapy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For further information on dosing of trastuzumab
and chemotherapy (which can cause side effects as well), please refer to the package
leaflet for these products. If you have questions about these medicines, please
ask your doctor or nurse. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>If you forget to have Perjeta</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you forget or miss your appointment to
receive Perjeta</span><span lang=EN-GB> </span><span lang=EN-GB>make another
appointment as soon as possible. If it has been 6 weeks or more since your last
visit</span><span lang=EN-GB> a </span><span lang=EN-GB>higher Perjeta dose of
840&nbsp;mg will be given to you.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>If you stop having Perjeta</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Do not stop having this medicine without
talking to your doctor first. It is important that you are given all the
infusions that have been recommended.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you have any further questions on the
use of this medicine, ask your doctor or nurse.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4. Possible
side effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Like all
medicines, this medicine can cause side effects, although not everybody gets
them.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Serious
side effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Tell a
doctor or nurse straight away, if you notice any of the following side effects:
</span></b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> Very severe or
persistent diarrhoea (7 or more stools per day).</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> A decrease in the
number or low amount of white blood cells (shown in a blood test), with or
without fever, which may increase the risk of an infection.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> Infusion
reactions with symptoms that can either be mild or more severe and may include
feeling sick (nausea), fever, chills, feeling tired, headache, loss of appetite,
joint and muscle pains, and hot flushes. </span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>Allergic and anaphylactic (more severe allergic) reactions with symptoms
that may include swelling of your face and throat, with difficulty </span><span
lang=EN-GB>in </span><span lang=EN-GB>breathing. Very rarely, patients have
died due to anaphylactic reactions during Perjeta infusion. </span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> Heart problems
(heart failure) with symptoms that can include cough, shortness of breath, and
swelling (fluid retention) in your legs or arms. </span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB style='font-family:Symbol'> </span><span
lang=EN-GB>Tumour lysis syndrome (a condition which may happen when cancer
cells die quickly, causing changes in blood levels of </span>minerals and
metabolites shown in a blood test). S<span lang=EN-GB>ymptoms may include
kidney problems (weakness, shortness of breath, fatigue and confusion), heart
problems (fluttering of the heart of a faster or slower heartbeat), seizures,
vomiting or diarrhoea and tingling in the mouth, hands or feet</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Tell a doctor or nurse straight away, if
you notice any of the side effects above. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Other side effects include:</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Very common (may affect more than 1 in
10 people):</span></b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> Diarrhoea</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB> Hair loss</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB> Feeling sick or being tired</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB> Rash</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB> Inflammation of your digestive tract (e.g. sore mouth)</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB> Decrease in the number of red blood cells  shown in a
blood test</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB> Joint or muscle pain, muscle weakness</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB> Constipation</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB> Reduced appetite</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB> Loss of or altered taste</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB> Fever </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB> Swollen ankles or other body parts due to your body
retaining too much water</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> Not being able to
sleep</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB> Hot flushes </span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> Weak, numb,
tingling or prickling sensations mainly affecting the feet and legs </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB> Nose bleeds</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB> Cough</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB> Heartburn</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB> Dry, itchy or acne like skin</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> Nail problems </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB> Sore throat, red, sore or runny nose, flu-like symptoms
and fever</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB> Producing more tears</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB> Fever associated with dangerously low levels of a type of
white blood cell (neutrophils)</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB> Pain in the body, arms, legs, and belly</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB> Shortness of breath</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB> Feeling dizzy</span></p>

<p class=MsoNormal><b><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal><b><span lang=EN-GB>Common (may affect up to 1 in 10
people):</span></b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> A feeling of
numbness, prickling or tingling in feet or hands; sharp jabbing, throbbing,
freezing or burning pain; feeling pain from something which should not be
painful such as a light touch; less able to feel changes in heat or cold; loss
of balance or coordination</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB> Inflammation of the nail bed where the nail and skin meet </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB> Infection of the ear, nose or throat</span></p>

<p class=MsoNormal style='margin-left:37.1pt;text-indent:-37.1pt'><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> Condition
in which the left ventricle of the heart is functionally impaired with or
without symptoms </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Uncommon (may affect up to 1 in 100 people):</span></b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> </span><span
lang=EN-GB>Chest symptoms such as a dry cough or breathlessness </span><span
lang=EN-GB>(possible signs of interstitial lung disease, a condition of damage
to the tissues around the air sacs in the lungs)</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB> Fluid around the lungs causing difficulty in breathing</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you experience any of the above symptoms
after treatment with Perjeta has been stopped, you should consult your doctor
immediately and inform him or her that you have previously been treated with
Perjeta.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Some of the side effects which you get may
be due to your breast cancer. If you are given Perjeta with trastuzumab and
chemotherapy at the same time, some side effects may also be due to these other
medicines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Reporting
of side effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>If you get
any side effects, talk to your doctor or nurse. This includes any possible side
effects not listed in this leaflet. </span><span lang=EN-GB>You can also report
side effects directly via </span><span lang=EN-GB style='background:lightgrey'>the
national reporting system listed in </span><a
href="https://www.ema.europa.eu/documents/template-form/appendix-v-adverse-drug-reaction-reporting-details_en.doc"><span
lang=EN-GB style='background:lightgrey'>Appendix V</span><span lang=EN-GB>.</span></a><span
lang=EN-GB> By reporting side effects you can help provide more information on
the safety of this medicine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>5. How
to store Perjeta</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Perjeta will
be stored by the health professionals at the hospital or clinic. The storage
details </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>are as
follows:</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> Keep this
medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> Do not use this
medicine after the expiry date which is stated on the outer carton after EXP.
The expiry date refers to the last day of that month.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> Store in a
refrigerator (2C-8C). </span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> Do not freeze.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> Keep the vial in
the outer carton in order to protect from light.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> Do not use this
medicine if you notice any particles in the liquid or it is the wrong colour
(please see section 6). </span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> Do not throw away
any medicines via wastewater or household waste. Ask your pharmacist how to
throw away medicines you no longer use. These measures will help to protect the
environment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>6. Contents of the pack and
other information</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>What Perjeta contains</span></b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> The active
substance is pertuzumab. Each vial contains a total of 420&nbsp;mg pertuzumab
at a concentration of 30&nbsp;mg/ml</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB> The other
ingredients are glacial acetic acid, L-histidine, sucrose, polysorbate 20 and
water for injections</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What Perjeta
looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Perjeta is a
concentrate for solution for infusion. It is a clear to slightly pearly
(opalescent), colourless to pale yellow liquid. It is supplied in a glass vial
containing 14&nbsp;ml concentrate.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Each pack
contains one vial.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Marketing
Authorisation Holder</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Roche Registration GmbH </span></p>

<p class=MsoNormal><span lang=EN-GB>Emil-Barell-Strasse 1</span></p>

<p class=MsoNormal><span lang=EN-GB>79639 Grenzach-Wyhlen</span></p>

<p class=MsoNormal><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=DE
style='color:black'>Roche Pharma AG </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=DE-CH
style='color:black'>Emil-Barell-Strasse 1</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>D-79639
Grenzach-Wyhlen</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Germany </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For any information about this medicine,
please contact the local representative of the Marketing Authorisation Holder:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR-CH>Belgi/Belgique/Belgien</span></b></p>
  <p class=MsoNormal><span lang=FR-CH>N.V. Roche S.A.</span></p>
  <p class=MsoNormal><span lang=FR>Tl/Tel: +32 (0) 2 525 82 11</span></p>
  <p class=MsoNormal><b><span lang=FR>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE-CH>Lietuva</span></b></p>
  <p class=MsoNormal><span lang=DE-CH>UAB Roche Lietuva</span></p>
  <p class=MsoNormal><span lang=DE-CH>Tel: +370 5 2546799</span></p>
  <p class=MsoNormal><b><span lang=DE-CH>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>&#1056;&#1086;&#1096;</span><span
  lang=EN-GB> </span><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span><span
  lang=EN-GB> </span><span lang=EN-GB>&#1045;&#1054;&#1054;&#1044;</span></p>
  <p class=MsoNormal><span lang=EN-GB>&#1058;&#1077;&#1083;</span>: +359
  2&nbsp;818 44 44</p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE-CH>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=DE-CH>(Voir/siehe Belgique/Belgien)</span></p>
  <p class=MsoNormal><span lang=DE-CH>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE-CH>&#268;esk republika</span></b></p>
  <p class=MsoNormal><span lang=DE-CH>Roche s. r. o.</span></p>
  <p class=MsoNormal><span lang=DE>Tel: +420 - 2 20382111</span></p>
  <p class=MsoNormal><span lang=DE>&nbsp;</span></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>Magyarorszg</span></b></p>
  <p class=MsoNormal><span lang=DE>Roche (Magyarorszg) Kft.</span></p>
  <p class=MsoNormal><span lang=DE>Tel: +36 - 23 446 800</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=DE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Danmark</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Roche a/s</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tlf: +45 - 36 39 99 99</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Malta</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>(See Ireland)</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE-CH>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=DE-CH>Roche Pharma AG</span></p>
  <p class=MsoNormal><span lang=DE-CH>Tel: +49 (0) 7624 140</span></p>
  <p class=MsoNormal><b><span lang=DE-CH>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE-CH>Nederland</span></b></p>
  <p class=MsoNormal><span lang=DE-CH>Roche Nederland B.V.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +31 (0) 348 438050</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Eesti</span></b></p>
  <p class=MsoNormal><span lang=IT>Roche Eesti O</span></p>
  <p class=MsoNormal><span lang=IT>Tel: + 372 - 6 177 380</span></p>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Norge</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Roche Norge AS</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tlf: +47 - 22 78 90 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Roche (Hellas) A.E. </span></p>
  <p class=MsoNormal><span lang=EN-GB>&#932;&#951;&#955;: +30 210 61 66 100</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE-CH>sterreich</span></b></p>
  <p class=MsoNormal><span lang=DE-CH>Roche Austria GmbH</span></p>
  <p class=MsoNormal><span lang=DE-CH>Tel: +43 (0) 1 27739</span></p>
  <p class=MsoNormal><span lang=DE-CH>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ES>Espaa</span></b></p>
  <p class=MsoNormal><span lang=ES>Roche Farma S.A.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +34 - 91 324 81 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Polska</span></b></p>
  <p class=MsoNormal><span lang=DE-CH>Roche Polska Sp.z o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +48 - 22 345 18 88</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>France</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Roche</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tl: +33&nbsp; (0)1 47 61 40 00</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT-BR>Portugal</span></b></p>
  <p class=MsoNormal><span lang=PT-BR>Roche Farmacutica Qumica, Lda</span></p>
  <p class=MsoNormal><span lang=PT-BR>Tel: +351 - 21 425 70 00</span></p>
  <p class=MsoNormal><span lang=PT-BR>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE-CH>Hrvatska</span></b></p>
  <p class=MsoNormal><span lang=DE-CH>Roche d.o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: + 385 1 47 22 333</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Romnia</span></b></p>
  <p class=MsoNormal><span lang=IT>Roche Romnia S.R.L.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +40 21 206 47 01</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Roche Products (Ireland) Ltd.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +353 (0) 1 469 0700</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Roche farmacevtska druba d.o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +386 - 1 360 26 00</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT-BR>sland </span></b></p>
  <p class=MsoNormal><span lang=PT-BR>Roche a/s</span></p>
  <p class=MsoNormal><span lang=PT-BR>c/o Icepharma hf</span></p>
  <p class=MsoNormal><span lang=PT-BR>Smi: +354 540 8000</span></p>
  <p class=MsoNormal><b><span lang=PT-BR>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DA>Slovensk republika </span></b></p>
  <p class=MsoNormal><span lang=DA>Roche Slovensko, s.r.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +421 - 2 52638201</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Italia</span></b></p>
  <p class=MsoNormal><span lang=IT>Roche S.p.A.</span></p>
  <p class=MsoNormal><span lang=DE-CH>Tel: +39 - 039 2471</span></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE-CH>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=DE-CH>Roche Oy<span style='layout-grid-mode:
  line'> </span></span></p>
  <p class=MsoNormal><span lang=DE-CH>Puh/Tel: +358 (0) 10 554 500</span></p>
  <p class=MsoNormal><span lang=DE-CH>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE-CH>K</span></b><b><span lang=EN-GB>&#973;&#960;&#961;&#959;&#962;</span></b><span
  lang=EN-GB style='font-size:10.0pt'> </span></p>
  <p class=MsoNormal><span lang=EN-GB>&#915;</span><span lang=DE-CH>.</span><span
  lang=EN-GB>&#913;</span><span lang=DE-CH>.</span><span lang=EN-GB>&#931;&#964;&#945;&#956;&#940;&#964;&#951;&#962;</span><span
  lang=DE-CH> &amp; </span><span lang=EN-GB>&#931;&#953;&#945;</span><span
  lang=EN-GB> </span><span lang=EN-GB>&#923;&#964;&#948;</span><span
  lang=DE-CH>.</span></p>
  <p class=MsoNormal><span lang=EN-GB>&#932;&#951;&#955;: +357 - 22 76 62 76</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Sverige</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Roche AB</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +46 (0) 8 726 1200</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Latvija</span></b></p>
  <p class=MsoNormal><span lang=IT>Roche Latvija SIA</span></p>
  <p class=MsoNormal><span lang=IT>Tel: +371 - 6 7039831</span></p>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>United Kingdom</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Roche Products Ltd.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +44 (0) 1707 366000</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>This
leaflet was last revised in. </span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-1.4pt'><span lang=EN-GB>Detailed
information on this medicine is available on the European Medicines Agency web
site: http://www.ema.europa.eu </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;text-autospace:none'><span
style='color:black'>&nbsp;</span></p>

</div>

</body>

</html>
